Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
i.e. BRD7232, inhibition kinetics; i.e. BRD7232, possesses kinetic selectivity for isozyme HDAC1 versus HDAC2, inhibition kinetics; inhibition kinetics
(2E)-3-[1,2-bis(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[1-benzyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[1-benzyl-2-(2-phenylethyl)-1H-benzimidazol-6-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[1-ethyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[1-[2-(diethylamino)ethyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[1-[3-(dimethylamino)-2,2-dimethylpropyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[1-[3-(dimethylamino)propyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[1-[4-(dimethylamino)butyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[2-cyclohexyl-1-(3-hydroxypropyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[2-[(benzyloxy)methyl]-1-(3-hydroxypropyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
-
-
(2E)-3-[4-([[2-(3a,7a-dihydro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]methyl)phenyl]-N-hydroxyprop-2-enamide
-
(2E)-N-(2-aminophenyl)-3-(4-{1-[(2-hydroxyethyl)amino]-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl}phenyl)prop-2-enamide
(2E)-N-(2-aminophenyl)-3-(4-{1-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl}phenyl)prop-2-enamide
(2E)-N-(2-aminophenyl)-3-[2-(2-phenylethyl)-1-(pyridin-2-ylmethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-(2-aminophenyl)-3-[4-(1-{[2-(morpholin-4-yl)ethyl]amino}-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl)phenyl]prop-2-enamide
(2E)-N-(2-aminophenyl)-3-{4-[2-(4-bromoanilino)-1-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl]phenyl}prop-2-enamide
(2E)-N-hydroxy-3-naphthalen-1-ylprop-2-enamide
-
HDAC8-selective inhibitor
(2E)-N-hydroxy-3-[1-(2-morpholin-4-ylethyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(1-methylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-methylpropyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-phenylpropyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-octyl-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-thiophen-3-yl-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-(3-methoxypropyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-(3-morpholin-4-ylpropyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-methyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-[3-(1H-imidazol-1-yl)propyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[1-[3-(2-oxopyrrolidin-1-yl)propyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(2-piperidin-1-ylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(2-pyrrolidin-1-ylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(3-pyrrolidin-1-ylpropyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(pyridin-2-ylmethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-propyl-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
-
-
(2E)-N-hydroxy-3-[2-[(4-methoxyphenyl)sulfonyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide
-
anti-proliferative activity in human HCT116 cell line, IC50 0.93 microM
(2E)-N-hydroxy-3-[2-[2-(1H-indol-3-yl)ethyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide
-
anti-proliferative activity in human HCT116 cell line, IC50 0.22 microM
(2E)-N-hydroxy-3-[2-[2-(2-methyl-1H-indol-3-yl)ethyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide
-
anti-proliferative activity in human HCT116 cell line, IC50 0.1042microM. Compound has a reasonable combination of potency, solubility and human microsomal stability to justify further investigation
(2E)-N-hydroxy-3-[2-[2-(pyrazolo[1,5-a]pyridin-3-yl)ethyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide
-
anti-proliferative activity in human HCT116 cell line, IC50 0.53 microM. Compound has a reasonable combination of potency, solubility and human microsomal stability to justify further investigation
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
-
(2R)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
-
(2S)-2-(acetylamino)-3-[3-[(2S)-2-[[(2S)-2-ammonio-7-(hydroxyamino)-7-oxoheptanoyl]amino]-3-methoxy-3-oxopropyl]phenyl]propanoate
-
-
(2S)-8-oxo-2-[(3-piperidin-1-ylpropanoyl)amino]-N-quinolin-3-ylnonanamide
-
-
(2S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]-2-fluorophenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-benzyl-N-(4-chlorophenyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(3-methylphenyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(4-methylphenyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(6-methylpyridin-3-yl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(piperidin-1-yl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(propan-2-yl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-2-yl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-3-yl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-4-yl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-phenylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-[4-(propan-2-yl)phenyl]pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2,4-difluorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2-chloro-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3,4-dichlorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3,4-difluorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-bromo-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-chloro-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-methoxyphenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-bromophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chloro-3-methylphenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2-difluoroethyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2-dimethylpropyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-fluoroethyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-hydroxy-2-methylpropyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-hydroxyethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-methoxyethyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(3-hydroxy-2,2-dimethylpropyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(cyanomethyl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(oxan-4-yl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(propan-2-yl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(pyrimidin-2-yl)pyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-cyclobutylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-ethylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-cyanophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-cyclopropylphenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-fluoro-3-methylphenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-methoxyphenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(5-chloropyridin-2-yl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-cyclopentyl-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-cyclopropyl-1-methylpyrrolidine-3-carboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N~3~-(4-chlorophenyl)-N~1~,N~1~-diethylpyrrolidine-1,3-dicarboxamide
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N~3~-(4-chlorophenyl)-N~1~-ethylpyrrolidine-1,3-dicarboxamide
(3R)-4-{5-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyrazin-2-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{5-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridin-2-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{6-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridazin-3-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R)-4-{6-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridin-3-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
(3R,4S)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
(3S)-3-{[(3S)-3-{[(benzyloxy)carbonyl]amino}-3-cyclopropylpropanoyl]amino}-2-oxo-5-phenylpentyl acetate
-
-
(3S,15R,20aS)-15-methyl-3-[(1E)-4-sulfanylbut-1-en-1-yl]-3,4,6,7,14,15,18,19,20,20a-decahydro-1H,5H,16H-11,8:15,12-di(azeno)pyrrolo[2,1-c][1,8,12,4,15]oxadithiadiazacyclooctadecine-1,5,16-trione
-
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
-
-
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
-
-
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
-
-
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
-
-
(4E)-N-(2-aminophenyl)-5-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]pent-4-enamide
-
(4Z)-6-[(5R,8S,11R)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-4-enoic acid
-
(5E)-N-(2-aminophenyl)-6-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-5-enamide
-
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
-
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3-thia-7,14,20,21-tetraazatricyclo[14.3.1.1-2,5]henicosa-1(20),2(21),16,18-tetraene-6,9,13-trione
-
(5R,8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
-
(5S,8R,11R)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
-
(5S,8S,11S,5'S,8'S,11'S)-11,11'-[disulfanediyldi(1E)but-1-ene-4,1-diyl]bis[5-methyl-8-(1-methylethyl)-3,10,17-trioxa-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione]
-
(8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),4,16(19)-tetraene-6,9,13-trione
-
(E)-3-(2-(((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)pyrimidin-5-yl)-N-hydroxyacrylamide
55% inhibition at 100 nM; 65% inhibition at 100 nM
(E)-3-[3-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]phenyl]-N-hydroxyacrylamide
-
inhibitor for both EGFR/HER2 kinase and HDAC with potent cellular activity, i.e. target inhibition and cytotoxicity
(E)-N-hydroxy-3-(2-(methyl((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidin-5-yl)acrylamide
60% inhibition at 100 nM; 61% inhibition at 100 nM
(E)-N1-hydroxy-N5-(5-styryl-1,3,4-thiadiazol-2-yl)glutaramide
-
antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.0059 and 0.00675 microM, respectively
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(naphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-m-tolyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-o-tolyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-p-tolyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-pentyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-phenethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride
-
(S)-benzyl 3-(biphenyl-4-ylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-benzyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-benzyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-N-(2,4-dimethylphenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-N-(3-chloro-4-fluorophenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-N-(3-chlorophenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-N-(4-fluorophenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-N-(biphenyl-4-yl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-N-benzyl-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride
-
(S)-N-hexyl-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-N-tert -butyl-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
-
(S)-tert-butyl 3-(2,4-dimethylphenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 3-(3-chloro-4-fluorophenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 3-(3-chlorophenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 3-(4-fluorophenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 3-(benzylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 3-(biphenyl-4-ylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 3-(hexylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 3-(tert-butylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(4-methoxyphenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(mtolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(naphthalen-1-ylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(o-tolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(p-tolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(pentylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
-
1,10-phenanthroline
10 mM, 66% inhibition
1-methyl-N-[(1S)-7-oxo-1-[(4-phenyl-1,3-thiazol-2-yl)carbamoyl]octyl]piperidine-2-carboxamide
-
-
1-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)thiophen-2-yl]-2,2,2-trifluoroethanone
-
-
1-[5-(4-acetylphenyl)thiophen-2-yl]-2,2,2-trifluoroethanone
-
-
15-deoxy-DELTA12,14-prostaglandin J2-biotin
-
maximal inhibition of recombinant HDAC3 in complex with CoR1 is 50%
2,2,2-trifluoro-1-(2-phenyl-1,3-thiazol-5-yl)ethanone
-
-
2,2,2-trifluoro-1-(4-phenylthiophen-2-yl)ethanone
-
-
2,2,2-trifluoro-1-(5-phenylthiophen-2-yl)ethanone
-
-
2,2,2-trifluoro-1-(5-[3-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
-
potent inhibitor of HDAC4 and shows more than 100fold selectivity overHDAC1
2,2,2-trifluoro-1-(5-[3-[(propylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
-
-
2,2,2-trifluoro-1-(5-[3-[(thiophen-2-ylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
-
-
2,2,2-trifluoro-1-[5-(1H-indol-5-yl)thiophen-2-yl]ethanone
-
-
2,2,2-trifluoro-1-[5-(2-methoxyphenyl)thiophen-2-yl]ethanone
-
-
2,2,2-trifluoro-1-[5-(3-methoxyphenyl)thiophen-2-yl]ethanone
-
-
2,2,2-trifluoro-1-[5-(3-methyl-1,2,4-oxadiazol-5-yl)thiophen-2-yl]ethanone
-
HDAC4-selective inhibitor
2,2,2-trifluoro-1-[5-(3-[[(4-fluorobenzyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl)thiophen-2-yl]ethanone
-
-
2,2,2-trifluoro-1-[5-(4-methoxyphenyl)thiophen-2-yl]ethanone
-
-
2,2,2-trifluoro-1-[5-(pyridin-2-yl)thiophen-2-yl]ethanone
-
-
2,2,2-trifluoro-1-[5-(quinoxalin-6-yl)thiophen-2-yl]ethanone
-
-
2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid (3,4-dimethylphenyl)-amide hydroxyamide
-
-
2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid biphenyl-2-ylamide hydroxyamide
-
-
2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid hydroxyamide (4-phenylthiazol-2-yl)amide
-
-
2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid hydroxyamide phenyl-amide
-
competitive. Significant but rather unselective inhibition of cellular HDACs
2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid hydroxyamide phenylamide
2,3-dihydrobenzoic acid
98% residual activity at 0.5 mM
2-(((3-(1-(2,4-difluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
66% inhibition at 100 nM; 88% inhibition at 100 nM
2-(((3-(1-(2-chloro-4-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
49% inhibition at 100 nM; 73% inhibition at 100 nM
2-(((3-(1-(2-chlorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
55% inhibition at 100 nM; 93% inhibition at 100 nM
2-(((3-(1-(2-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
44% inhibition at 100 nM; 84% inhibition at 100 nM
2-(((3-(1-(4-cyanobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
38% inhibition at 100 nM; 68% inhibition at 100 nM
2-(((3-(1-(4-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
65% inhibition at 100 nM; 92% inhibition at 100 nM
2-(((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
63% inhibition at 100 nM; 96% inhibition at 100 nM
2-(3,6-dihydroxy-9H-xanthen-9-yl)-5-(8-(hydroxyamino)-8-oxooctanamido)benzoic acid
synthesis, overview
2-(3,6-dihydroxy-9H-xanthen-9-yl)-5-(8-methoxy-8-oxooctanamido)benzoic acid
synthesis, overview
2-(4-((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacetamide
18% inhibition at 100 nM; 35% inhibition at 100 nM
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)nonyl]acetamide
-
-
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide
-
-
2-hydroxybutyric acid
96% residual activity at 0.5 mM
2-[(methylsulfonyl)sulfanyl]ethanaminium bromide
-
-
2-[(methylsulfonyl)sulfanyl]ethyl 2-propylpentanoate
-
-
3,4-Dihydroxyphenyl acetic acid
90% residual activity at 0.5 mM
3-(1-methyl-4-phenylacetyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide
APHA
3-(4-((3-(1-(2,4-difluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
35% inhibition at 100 nM; 74% inhibition at 100 nM
3-(4-((3-(1-(2-chlorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
59% inhibition at 100 nM; 8% inhibition at 100 nM
3-(4-((3-(1-(2-cyanobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
36% inhibition at 100 nM; 65% inhibition at 100 nM
3-(4-((3-(1-(2-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
31% inhibition at 100 nM; 68% inhibition at 100 nM
3-(4-((3-(1-(3,4-difluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
17% inhibition at 100 nM; 60% inhibition at 100 nM
3-(4-((3-(1-(3-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
35% inhibition at 100 nM; 73% inhibition at 100 nM
3-(4-((3-(1-(4-bromobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
58% inhibition at 100 nM; 6% inhibition at 100 nM
3-(4-((3-(1-(4-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
38% inhibition at 100 nM; 75% inhibition at 100 nM
3-(4-((3-(1-allylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
34% inhibition at 100 nM; 66% inhibition at 100 nM
3-(4-((3-(1-allylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxypropanamide
15% inhibition at 100 nM; 4% inhibition at 100 nM
3-(4-((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N- hydroxypropanamide
11% inhibition at 100 nM; 22% inhibition at 100 nM
3-(4-((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-N-hydroxyacrylamide
35% inhibition at 100 nM; 71% inhibition at 100 nM
3-benzoylbenzoic acid
-
and hydroxamate analogs
3-benzoylpropanoic acid
-
and hydroxamate analogs
3-hydroxycinnamic acid
96% residual activity at 0.5 mM
3-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
-
the inhibitor shows 40fold selectivity for HDAC4 and 180fold for HDAC6 against HDAC1
3-[5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2-(2-phenylethyl)-1H-benzimidazol-1-yl]propanoic acid
-
-
3-[5-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]furan-2-yl]-N-hydroxy-acrylamide
-
inhibitor for both EGFR/HER2 kinase and HDAC with potent cellular activity, i.e. target inhibition and cytotoxicity
4-((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)-N-hydroxybenzamide
29% inhibition at 100 nM; 66% inhibition at 100 nM
4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-propylpentanoate
-
-
4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
M344
4-benzoylbutyric acid
-
and hydroxamate analogs
4-benzoylbutyric hydroxamic acid
-
-
4-hydroxy-2-nonenal
-
maximal inhibition of recombinant HDAC3 in complex with CoR1 is 70%
4-phenylbutyric acid
-
and hydroxamate analogs
4-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
-
-
4-[5-(trifluoroacetyl)thiophen-2-yl]benzonitrile
-
-
4-[[(2E)-2-(2-chlorobenzylidene)hydrazinyl]carbonothioyl]-N-hydroxypiperazine-1-carboxamide
-
4-[[(2E)-2-(4-chlorobenzylidene)hydrazinyl]carbonothioyl]-N-hydroxypiperazine-1-carboxamide
inactivates HDAC8 preferentially over HDAC1
4-[[(2E)-2-(anthracen-9-ylmethylidene)hydrazinyl]carbonothioyl]-N-hydroxypiperazine-1-carboxamide
-
5-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxypentanamide
-
-
5-(4-hydroxyphenyl)-3H-1,2-dithiol-3-thione
-
-
5-phenylvaleric acid
-
and hydroxamate analogs
5-phenylvaleric hydroxamic acid
-
-
6-mercapto-N-phenylhexanamide
-
6-[(1-(mercaptomethyl)vinyl)amino]-N-phenylhexanamide
-
6-[(2E)-2-[(2-bromo-4-hydroxy-5-methoxyphenyl)methylidene]hydrazino]-N-hydroxy-6-oxohexanamide
-
6-[(2E)-2-[(2-bromo-4-hydroxyphenyl)methylidene]hydrazino]-N-hydroxy-6-oxohexanamide
-
6-[(2E)-2-[(2-bromo-5-hydroxyphenyl)methylidene]hydrazino]-N-hydroxy-6-oxohexanamide
-
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
-
-
6-[(9H-fluoren-3-ylmethyl)(3-phenoxybenzyl)amino]-N-hydroxyhexanamide
6-[(biphenyl-4-ylmethyl)[4-[(4-bromobenzyl)oxy]benzyl]amino]-N-hydroxyhexanamide
-
-
6-[4-(2,6-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide
-
-
6-[4-(biphenyl-2-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide
-
-
6-[4-(biphenyl-3-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide
-
-
6-[4-(biphenyl-4-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide
-
-
6-[[4-[(4-bromobenzyl)oxy]benzyl](9H-fluoren-3-ylmethyl)amino]-N-hydroxyhexanamide
-
-
6-{4-[4-(dimethylamino)phenyl]-1H-1,2,3-triazol-1-yl}-N-hydroxyhexanamide
-
-
7-mercapto-N-(2-phenyl-1,3-thiazol-5-yl)heptanamide
-
7-mercapto-N-(3-phenoxyphenyl)heptanamide
-
7-mercapto-N-phenylheptanamide
thiol formed by enzymatic hydrolysis in the cell reacts with the zinc ion in the active site of histone deacetylase. Molecular modeling of complex with histone HDAC8
7-mercapto-N-pyridin-3-ylheptanamide
-
7-mercapto-N-quinolin-3-ylheptanamide
-
7-[(2E)-2-[(2-bromo-4-hydroxy-5-methoxyphenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
-
7-[(2E)-2-[(2-bromo-5-hydroxyphenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
-
7-[(2E)-2-[(2-bromo-5-methoxyphenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
-
7-[(2E)-2-[(2-bromophenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
-
7-[(2E)-2-[(2-bromopyridin-3-yl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
-
7-[(2E)-2-[(2-chlorophenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
-
7-[(2E)-2-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
-
7-[(2E)-2-[[4-(dimethylamino)-2-hydroxyphenyl]methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
-
7-[4-(biphenyl-3-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyheptanamide
-
-
7-{4-[4-(dimethylamino)phenyl]-1H-1,2,3-triazol-1-yl}-N-hydroxyheptanamide
-
-
8-hydroxyquinoline
85% residual activity at 0.5 mM
8-[(2E)-2-[(2,5-dihydroxyphenyl)methylidene]hydrazino]-N-hydroxy-8-oxooctanamide
-
acetylated histone deacetylase 1
-
the activity of HDAC2 is inhibited by acetylated HDAC1
-
allyl mercaptan
garlic organosulfur compounds can be metabolized to allyl mercaptan
alpha-keto-gamma-methylselenobutyrate
causes dose-dependent inhibition of HDAC activity, HDAC1 shows about 80% residual activity at 2 mM, HDAC8 shows less than 60% residual activity at 2 mM
Baclofen
98% residual activity at 0.5 mM
beta-methylselenopyruvate
causes dose-dependent inhibition of HDAC activity, competitive inhibitor of HDAC8, HDAC1 shows about 30% residual activity at 2 mM, HDAC8 shows less than 30% residual activity at 2 mM
caffeic acid
80% residual activity at 0.5 mM
chlorogenic acid
highly potent HDAC inhibitor, 40% residual activity at 0.5 mM
Cinnamic acid
95% residual activity at 0.5 mM
curcumin
highly potent HDAC inhibitor, 52% residual activity at 0.5 mM
cyclo (N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxodecanoyl)
-
i.e. apicidin, a cyclic tetrapeptide having broad-spectrum antiparasitic activity, inhibits the enzyme activity as well as the in vitro growth of Babesia parasites with an IC50 of 3.8 ng/ml
D-(-)-quinic acid
96% residual activity at 0.5 mM
dihydrocaffeic acid
86% residual activity at 0.5 mM
EDTA
-
1 mM, 30 min, complete loss of activity. Zn2+, Mg2+, Mn2+ may restore activity
ferulic acid
80% residual activity at 0.5 mM
FOXP
-
FOXP3 specifically inhibits binding of histone deacetylase 2 and 4 to the site and increases local histone H3 acetylation
-
FR901228
-
Gal4-dHDAC1, consisting of the N-terminal 147 amino acid residues of the yeast Gal4 protein fused to the N terminus of full-length dHDAC1 protein, but not dHDAC1, is able to repress transcription in vitro. Transcriptional repression is blocked by the enzyme inhibitor FR901228
gamma-aminobutyric acid
-
indol-2-carboxylic acid
97% residual activity at 0.5 mM
isobutyric acid
80% residual activity at 0.5 mM
Isothiocyanate
found in cruciferous vegetables
JNJ-26481585
-
broad-spectrum or pan-HDAC inhibitor
K+
-
K+ bound to monovalent cation site 1 inhibits catalytic activity of HDAC8 (11fold less active with two K+ ions bound compared to one K+ ion bound), partial inhibition at high KCl
Mandelic acid
85% residual activity at 0.5 mM
MC1568
specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs
MC1575
specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs; specificity for class II HDACs
MCP30
30 kDa protein isolated from bitter melon seeds, Momordica charantia, contains two highly related type I ribosome-inactivating proteins, alpha- and beta-momorcharin
-
methyl (3R,6R,9R)-9-(acetylamino)-6-[6-(hydroxyamino)-6-oxohexyl]-5,8-dioxo-4,7-diazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3-carboxylate
-
tight binding competitive inhibition
methyl N-[(2S)-2-[(N-acetyl-L-alanyl)amino]-7-(hydroxyamino)-7-oxoheptanoyl]-L-phenylalaninate
-
-
MGCD 290
-
an enzyme Hos2 inhibitor, for use in combination with azoles, such as fluconazole, for fungal infections
-
N-(2-aminophenyl)-4-[[(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]methyl]benzamide
-
-
N-(2-aminophenyl)-4-[[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]methyl]benzamide
-
-
N-(2-aminophenyl)-5-[(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide
-
-
N-(2-aminophenyl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide
-
-
N-(2-aminophenyl)-6-(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)hexanamide
-
-
N-(2-aminophenyl)-6-(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)hexanamide
-
-
N-(2-aminopyridin-3-yl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide
-
-
N-(2-hydroxyphenyl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide
-
-
N-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
-
N-(4-amino-4'-chloro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-1H-2-benzopyran-3-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-2H-1-benzopyran-3-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3-oxabicyclo[3.1.0]hexane-6-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
i.e. BRD4884, coordinates to the Zn2+ ion via the free aniline -NH2, completing its tetrahedral coordination sphere in addition to the side chains of Asp181, His183, and Asp269 with the anilide carbonyl oxygen situated at a distance of 2.8 A to the Zn2+ ion. The anilide-NH of BRD4884 forms an H-bond to the backbone carbonyl oxygen of Gly154. The 11 A lipophilic channel harbors the tetrahydropyran moiety of BRD4884 making Van Der Waals contacts with the channel wall. The tetrahydropyran ring adopts a preferential chair conformation allowing the pyran oxygen atom to form a hydrogen bond (3.5 A) with a conserved water at the surface of HDAC2, inhibition kinetics; i.e. BRD4884, possesses kinetic selectivity for isozyme HDAC1 versus HDAC2, inhibition kinetics; inhibition kinetics
N-(4-aminopyrimidin-5-yl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide
-
-
N-(4-amino[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
-
N-(6-mercaptohexyl)-1-benzofuran-2-carboxamide
-
N-(6-mercaptohexyl)-1H-indole-2-carboxamide
-
N-(6-mercaptohexyl)-2-naphthamide
-
N-(6-mercaptohexyl)benzamide
-
N-(8,8,8-trifluoro-7-oxooctyl)benzamide
-
-
N-(8-aminonaphthalen-1-yl)-5-[(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide
-
-
N-(8-aminonaphthalen-1-yl)-5-[(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)sulfanyl]pentanamide
-
-
N-(8-aminonaphthalen-1-yl)-6-(4-biphenyl-4-yl-6-oxo-1,6-dihydropyrimidin-2-yl)hexanamide
-
-
N-(8-aminonaphthalen-1-yl)-6-(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)hexanamide
-
-
N-biphenyl-3-yl-7-mercaptoheptanamide
-
N-hydroxy-1-(3-hydroxypropyl)-2-(2-phenylethyl)-1H-benzimidazole-5-carboxamide
-
-
N-hydroxy-1-methyl-indole-6-carboxamide
-
HDAC8-selective inhibitor
N-hydroxy-2-(methyl((3-(1-(3-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidine-5-carboxamide
54% inhibition at 100 nM; 93% inhibition at 100 nM
N-hydroxy-2-(methyl((3-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidine-5-carboxamide
30% inhibition at 100 nM; 62% inhibition at 100 nM
N-hydroxy-2-(methyl((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidine-5-carboxamide
71% inhibition at 100 nM; 96% inhibition at 100 nM
N-hydroxy-2-[1-methyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]cyclopropanecarboxamide
-
-
N-hydroxy-3-(4-((3-(1-(2-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide
14% inhibition at 100 nM; 68% inhibition at 100 nM
N-hydroxy-3-(4-((3-(1-(2-nitrobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide
19% inhibition at 100 nM; 63% inhibition at 100 nM
N-hydroxy-3-(4-((3-(1-(3-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide
25% inhibition at 100 nM; 73% inhibition at 100 nM
N-hydroxy-3-(4-((3-(1-(4-methoxybenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide
36% inhibition at 100 nM; 75% inhibition at 100 nM
N-hydroxy-3-(4-((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide
32% inhibition at 100 nM; 76% inhibition at 100 nM
N-hydroxy-3-(4-((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propanamide
12% inhibition at 100 nM; 28% inhibition at 100 nM
N-hydroxy-3-(4-((3-(1-propylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)acrylamide
40% inhibition at 100 nM; 69% inhibition at 100 nM
N-hydroxy-3-(4-((3-(1-propylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propanamide
13% inhibition at 100 nM; 5% inhibition at 100 nM
N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-methylpropyl)-1H-benzimidazol-5-yl]propanamide
-
-
N-hydroxy-3-[2-(2-phenylethyl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazol-5-yl]propanamide
-
-
N-hydroxy-3-[2-[(2-methyl-1H-indol-3-yl)acetyl]-2,3-dihydro-1H-isoindol-5-yl]propanamide
-
anti-proliferative activity in human HCT116 cell line, IC50 0.19 microM
N-hydroxy-4-(methyl[(5-pyridin-2-yl-2-thienyl)sulfonyl]amino)benzamide
-
N-hydroxy-4-[[(2E)-2-(2-hydroxybenzylidene)hydrazinyl]carbonothioyl]piperazine-1-carboxamide
inactivates HDAC8 preferentially over HDAC1
N-hydroxy-4-[[(2E)-2-(4-methylbenzylidene)hydrazinyl]carbonothioyl]piperazine-1-carboxamide
-
N-hydroxy-4-[[(2Z)-2-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazinyl]carbonothioyl]piperazine-1-carboxamide
-
N-hydroxy-4-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}butanamide
N-hydroxy-5-(4-phenyl-1H-1,2,3-triazol-1-yl)pentanamide
-
-
N-hydroxy-5-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}pentanamide
N-hydroxy-6-(4-phenyl-1H-1,2,3-triazol-1-yl)hexanamide
-
-
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
-
-
N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide
-
-
N-hydroxy-6-[4-(2-methoxyphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(3-methylphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(4-methylphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(6-methoxynaphthalen-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(quinolin-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(quinolin-7-yl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-[4-(thiophen-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide
-
-
N-hydroxy-6-{4-[4-(pyridin-4-yl)phenyl]-1H-1,2,3-triazol-1-yl}hexanamide
-
-
N-hydroxy-6-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}hexanamide
N-hydroxy-7-(4-phenyl-1H-1,2,3-triazol-1-yl)heptanamide
-
-
N-hydroxy-7-[(2E)-2-[(2-hydroxynaphthalen-1-yl)methylidene]hydrazino]-7-oxoheptanamide
-
N-hydroxy-7-[(2E)-2-[(3-hydroxyphenyl)methylidene]hydrazino]-7-oxoheptanamide
-
N-hydroxy-7-[(2E)-2-[[4-(1H-imidazol-1-yl)phenyl]methylidene]hydrazino]-7-oxoheptanamide
-
N-hydroxy-7-[4-(6-methoxynaphthalen-2-yl)-1H-1,2,3-triazol-1-yl]heptanamide
-
-
N-hydroxy-7-[4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl]heptanamide
-
-
N-hydroxy-7-{4-[4-(pyridin-4-yl)phenyl]-1H-1,2,3-triazol-1-yl}heptanamide
-
-
N-hydroxy-7-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}heptanamide
N-hydroxy-8-oxo-8-[(2E)-2-[(2,4,6-trihydroxyphenyl)methylidene]hydrazino]octanamide
-
N-hydroxy-8-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}octanamide
N-hydroxy-N~3~-[5-(propan-2-yl)naphthalene-1-sulfonyl]-beta-alaninamide
N-hydroxynaphthalene-1-carboxamide
-
HDAC8-selective inhibitor
N-methyl-N-(quinoxalin-6-ylmethyl)-5-(trifluoroacetyl)thiophene-2-carboxamide
-
-
N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
-
-
N-[(2E)-3-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]prop-2-en-1-yl]-2-sulfanylacetamide
-
N-[(3E)-4-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-en-1-yl]-2-sulfanylacetamide
-
N-[1,1,2,2,3,3,4,4,5,5,6,6-dodecafluoro-7-(hydroxyamino)-7-oxoheptyl]benzamide
a highly selective hydroxamate inhibitor
N-[2-amino-5-(pyridin-3-yl)phenyl]oxane-4-carboxamide
-
N-[2-amino-5-(pyridin-4-yl)phenyl]oxane-4-carboxamide
-
N-[4-amino-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxane-4-carboxamide
-
N1-(5-benzyl-1,3,4-thiadiazol-2-yl)-N7-hydroxyheptanediamide
-
antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.0061 and 0.0122 microM, respectively
N1-(5-benzyl-1,3,4-thiadiazol-2-yl)-N8-hydroxyoctanediamide
-
antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.00298 and 0.0091 microM, respectively
N1-hydroxy-N7-(5-phenyl-1,3,4-thiadiazol-2-yl)heptanediamide
-
antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.0055 and 0.0129 microM, respectively
N1-hydroxy-N8-(5-phenyl-1,3,4-thiadiazol-2-yl)octanediamide
-
-
N1-methyl-2-oxo-N9-phenylnonanediamide
-
NaCl
inhibitory in sodium phosphate/citric acid buffer, 50% inhibition at 100 mM
p300
-
p300 can inactivate HDAC6 by acetylation
-
PCI-24781
-
broad-spectrum or pan-HDAC inhibitor
PCI-34051
-
HDAC8-selective inhibitor
peroxynitrite
activity of wild-type enzyme is reduced to 38% in presence of peroxynitrite. Activities of mutants Y153A and Y253A are 233 completely abolished in the presence of peroxynitrite. Mutant Y146A shows 32% reduction in activity
propionic acid
80% residual activity at 0.5 mM
pyridin-3-ylmethyl (4-[[(2-aminophenyl)amino]carbonyl]benzyl)carbamate
i.e. MS27-275
S-(2-hydroxyethyl) methanesulfonothioate
-
-
S-nitrosocysteine
the activity of HDAC8 is significantly inhibited when incubated with S-nitrosoglutathione and S-nitrosocysteine in a time- and dosage-dependent manner. Sodium nitroprusside and dithiothreitol cannot reverse this inhibition
S-nitrosoglutathione
HDAC8 can be S-nitrosylated by S-nitrosoglutathione in vitro, and the activity of HDAC8 is significantly inhibited when incubated with S-nitrosoglutathione and S-nitrosocysteine in a time- and dosage-dependent manner. Sodium nitroprusside and dithiothreitol cannot reverse this inhibition
S-[2-[(2-propylpentanoyl)amino]ethyl]methanesulfonothioate
-
-
S-[7-oxo-7-(2-phenyl1,3-thiazol-5-ylamino)heptyl] 2-methylpropanethioate
analysis of growth inhibition of various cancer cells and comparison with suberoylanilide hydroxamic acid
salicylic acid
92% residual activity at 0.5 mM
SK7041
-
i.e. 4-dimethylamino-N-[4-(2-hydroxylcarbamoyl-vinyl)benzyl] benzamide
sorbic acid
91% residual activity at 0.5 mM
suberoyl anilide hydroxamic acid
suberoylanilide hydroxamic acid
suberoylanilide hydroxyamic acid
-
a specific inhibitor of zinc-dependent histone deacetylase activity. The compound directly induces p19INK4d expression in regenerating liver by increasing p19INK4d promoter-associated histone acetylation, molecular mechanisms by which the inhibitor delays liver regeneration exerting promoter-specific effects on histone acetylation during liver regeneration, overview
suberoylanilide trifluoromethylketone
tartaric acid
90% residual activity at 0.5 mM
trichostatinA
TSA, treatment with the specific HDAC inhibitor induces the enzyme HDA1, effectively inhibits AhHDA1 activity
Valeric acid
83% residual activity at 0.5 mM
Valproate
-
class I-selective HDAC inhibitor
[4-[(E)-[[6-(hydroxyamino)-6-oxohexanoyl]hydrazono]methyl]phenyl]boronic acid
-
(2E)-N-(2-aminophenyl)-3-(4-{1-[(2-hydroxyethyl)amino]-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl}phenyl)prop-2-enamide
-
(2E)-N-(2-aminophenyl)-3-(4-{1-[(2-hydroxyethyl)amino]-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl}phenyl)prop-2-enamide
-
(2E)-N-(2-aminophenyl)-3-(4-{1-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl}phenyl)prop-2-enamide
-
(2E)-N-(2-aminophenyl)-3-(4-{1-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl}phenyl)prop-2-enamide
-
(2E)-N-(2-aminophenyl)-3-[4-(1-{[2-(morpholin-4-yl)ethyl]amino}-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl)phenyl]prop-2-enamide
-
(2E)-N-(2-aminophenyl)-3-[4-(1-{[2-(morpholin-4-yl)ethyl]amino}-2-oxo-2-[4-(trifluoromethyl)anilino]ethyl)phenyl]prop-2-enamide
-
(2E)-N-(2-aminophenyl)-3-{4-[2-(4-bromoanilino)-1-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl]phenyl}prop-2-enamide
-
(2E)-N-(2-aminophenyl)-3-{4-[2-(4-bromoanilino)-1-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl]phenyl}prop-2-enamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]-2-fluorophenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]-2-fluorophenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-benzyl-N-(4-chlorophenyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-benzyl-N-(4-chlorophenyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(3-methylphenyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(3-methylphenyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(4-methylphenyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(4-methylphenyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(6-methylpyridin-3-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(6-methylpyridin-3-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(piperidin-1-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(piperidin-1-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(propan-2-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(propan-2-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-2-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-2-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-3-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-3-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-4-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-(pyridin-4-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-phenylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-phenylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-[4-(propan-2-yl)phenyl]pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-[4-(propan-2-yl)phenyl]pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-1-methyl-N-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2,4-difluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2,4-difluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2-chloro-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2-chloro-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(2-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3,4-dichlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3,4-dichlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3,4-difluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3,4-difluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-bromo-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-bromo-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-chloro-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-chloro-4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-methoxyphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(3-methoxyphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-bromophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-bromophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chloro-3-methylphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chloro-3-methylphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2-difluoroethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2-difluoroethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2-dimethylpropyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2,2-dimethylpropyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-fluoroethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-fluoroethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-methoxyethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-methoxyethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(3-hydroxy-2,2-dimethylpropyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(3-hydroxy-2,2-dimethylpropyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(cyanomethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(cyanomethyl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(oxan-4-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(oxan-4-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(propan-2-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(propan-2-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(pyrimidin-2-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(pyrimidin-2-yl)pyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-cyclobutylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-cyclobutylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-ethylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-ethylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-cyanophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-cyanophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-cyclopropylphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-cyclopropylphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-fluoro-3-methylphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-fluoro-3-methylphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-fluorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-methoxyphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-methoxyphenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(5-chloropyridin-2-yl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(5-chloropyridin-2-yl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-cyclopentyl-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-cyclopentyl-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-cyclopropyl-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-cyclopropyl-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N~3~-(4-chlorophenyl)-N~1~,N~1~-diethylpyrrolidine-1,3-dicarboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N~3~-(4-chlorophenyl)-N~1~,N~1~-diethylpyrrolidine-1,3-dicarboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N~3~-(4-chlorophenyl)-N~1~-ethylpyrrolidine-1,3-dicarboxamide
-
(3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N~3~-(4-chlorophenyl)-N~1~-ethylpyrrolidine-1,3-dicarboxamide
-
(3R)-4-{5-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyrazin-2-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{5-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyrazin-2-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{5-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridin-2-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{5-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridin-2-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{6-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridazin-3-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{6-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridazin-3-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{6-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridin-3-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R)-4-{6-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]pyridin-3-yl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R,4S)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
(3R,4S)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide
-
2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid hydroxyamide phenylamide
-
2,2,3,3,4,4,5,5,6,6,7,7-dodecafluorooctanedioic acid hydroxyamide phenylamide
-
6-[(9H-fluoren-3-ylmethyl)(3-phenoxybenzyl)amino]-N-hydroxyhexanamide
simultaneous and efficient interactions of compound with both the enzyme surface and the tubular binding pocket, through proper selection of its arm groups, are critical for potential antagonist activity
6-[(9H-fluoren-3-ylmethyl)(3-phenoxybenzyl)amino]-N-hydroxyhexanamide
-
-
apicidin
-
apicidin
-
natural inhibitor
belinostat
-
PXD101
belinostat
i.e. PXD-101; i.e. PXD-101
Butyrate
-
non-competitive
Butyrate
-
inhibition of histone deacetylase activity, resulting in prevention of interferon gamma-induced Janus kinase 1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation
Butyrate
-
class I-selective HDAC inhibitor
Butyrate
-
inhibition of histone deacetylases, results in down-regulation of HoxA9 expression
Butyric acid
-
-
chidamide
-
entinostat
-
MS-275
FK-228
-
natural inhibitor
HC-toxin
-
cyclic peptide inhibitor from Cochliobolus carbonum. Histone deacetylase in crude extracts of Alternaria brassicola is relatively insensitive to inhibition, such as enzyme from Cochliobolus carbonum. Comparison of sensitivity in various Cochliobolus carbonum strains and in several other fungi
HC-toxin
cyclic peptide inhibitor from Cochliobolus carbonum. Histone deacetylase in crude extracts of Cochliobolus carbonum is relatively insensitive to inhibition. Comparison of sensitivity in various Cochliobolus carbonum strains and in several other fungi. Resistance genetically cosegregates with toxin production
HC-toxin
-
cyclic peptide inhibitor from Cochliobolus carbonum. Histone deacetylase in crude extracts of Diheterospora chlamydosporia is relatively insensitive to inhibition, such as enzyme from Cochliobolus carbonum. Comparison of sensitivity in various Cochliobolus carbonum strains and in several other fungi
ITF-2357
-
broad-spectrum or pan-HDAC inhibitor
LAQ824
-
enzyme inhibition results in altered Toll-like receptor 4-dependent activation and function of macrophages and dendritic cells. Pan-HDAC inhibition modulates only a limited set of genes involved in distinct arms of immune responses, specifically dendritic cell-controlled T helper 1 effector, but not T helper 2 effector cell activation and migration. It also inhibits dendritic cell-mediated monocyte, but not neutrophil chemotaxis
LAQ824
-
pan-HDAC inhibitor
largazole
-
-
largazole
FK228; FK228; FK228; FK228
LBH-589
-
panobinostat, broad-spectrum or pan-HDAC inhibitor
LBH589
-
LBH589
-
pan-histone deacetylase inhibitor
MGCD-0103
-
mocetinostat dihydrobromide, class I-selective HDAC inhibitor
mocetinostat
-
MS-275
-
56.3% inhibition at 0.01 mM, 46.3% inhibition at 0.001 mM
MS-275
-
SNDX-275, entinostat, class I-selective HDAC inhibitor
MS-275
-
inhibition of HDAC1 leads to a significant increase of global acetylation of residues K9 and K14 on histone H3, which is a feature of active transcription, and a significant induction of proinflammatory cytokine expression. Genomic DNA corresponding to the IL1beta and IL6 promoter is significantly enriched upon HDAC 1 inhibition
MS-275
-
inhibition of histone deacetylases, results in down-regulation of HoxA9 expression
N-hydroxy-4-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}butanamide
-
N-hydroxy-4-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}butanamide
-
N-hydroxy-5-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}pentanamide
-
N-hydroxy-5-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}pentanamide
-
N-hydroxy-6-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}hexanamide
-
N-hydroxy-6-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}hexanamide
-
N-hydroxy-7-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}heptanamide
-
N-hydroxy-7-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}heptanamide
-
N-hydroxy-8-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}octanamide
-
N-hydroxy-8-{[5-(propan-2-yl)naphthalene-1-sulfonyl]amino}octanamide
-
N-hydroxy-N~3~-[5-(propan-2-yl)naphthalene-1-sulfonyl]-beta-alaninamide
-
N-hydroxy-N~3~-[5-(propan-2-yl)naphthalene-1-sulfonyl]-beta-alaninamide
-
panobinostat
LBH-589
panobinostat
i.e. LBH-589; i.e. LBH-589
PXD-101
-
belinostat, broad-spectrum or pan-HDAC inhibitor
resminostat
-
romidepsin
-
FK228
romidepsin
-
FK-228, FR901228, depsipeptide, class I-selective HDAC inhibitor
romidepsin
i.e. FK-228; i.e. FK-228
SAHA
-
-
SAHA
i.e. vorinostat; i.e. vorinostat
shRNA
-
-
-
sodium butyrate
-
-
sodium butyrate
-
pan-HDAC inhibitor
suberoyl anilide hydroxamic acid
-
suberoyl anilide hydroxamic acid
-
-
suberoylanilide hydroxamic acid
-
suberoylanilide hydroxamic acid
-
-
suberoylanilide hydroxamic acid
-
suberoylanilide hydroxamic acid
-
inhibition of histone deacetylase activity, resulting in prevention of interferon gamma-induced Janus kinase 1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation
suberoylanilide hydroxamic acid
-
suberoylanilide hydroxamic acid
-
-
suberoylanilide hydroxamic acid
-
suberoylanilide hydroxamic acid
SAHA
suberoylanilide hydroxamic acid
-
-
suberoylanilide hydroxamic acid
-
SAHA, vorinostat, zolinza, broad-spectrum or pan-HDAC inhibitor
suberoylanilide hydroxamic acid
-
SAHA, synthetic inhibitor
suberoylanilide hydroxamic acid
SAHA
suberoylanilide hydroxamic acid
-
SAHA, vorinostat
suberoylanilide hydroxamic acid
SAHA
suberoylanilide hydroxamic acid
SAHA, vorinostat
suberoylanilide hydroxamic acid
-
SAHA
suberoylanilide hydroxamic acid
SAHA; SAHA; SAHA; SAHA; SAHA
suberoylanilide hydroxamic acid
-
suberoylanilide hydroxamic acid
-
-
suberoylanilide hydroxamic acid
-
pan-HDAC inhibitor
suberoylanilide hydroxamic acid
-
-
suberoylanilide hydroxamic acid
-
i.e. SAHA, antiproliferative activities against MDA-MB-231 and K562 cell lines, IC50 0.00132 and 0.00169 microM, respectively
suberoylanilide hydroxamic acid
complete inhibition; complete inhibition
suberoylanilide hydroxamic acid
SAHA, Ki, for the T-cell lymphoma drug suberoylanilide hydroxamic acid (SAHA) is different for each metal-substituted HDAC8
suberoylanilide hydroxamic acid
SAHA
suberoylanilide hydroxamic acid
-
SAHA
suberoylanilide trifluoromethylketone
-
suberoylanilide trifluoromethylketone
-
sulforaphane
-
at 0.015 mM, 40, 30 and 40% inhibition of histone deacetylase activities in BPH-1, LnCaP and PC-3 prostate epithelial cells, resp. Inhibition is accompanied by a 50-100% increase in acetylated histones. BPH-1 cells treated with inhibitor show enhanced interaction of acetylated histone H4 with the promoter region of the P21 gene and the bax gene
sulforaphane
SFN, found in broccoli sprouts
trapoxin
-
-
trapoxin B
-
natural inhibitor
trichostatin A
-
trichostatin A
TSA, a HDAC inhibitor; TSA, a HDAC inhibitor
trichostatin A
-
inhibition of histone deacetylase activity, resulting in prevention of interferon gamma-induced Janus kinase 1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation
trichostatin A
-
natural inhibitor
trichostatin A
TSA; TSA; TSA; TSA; TSA
trichostatin A
-
inhibition of histone deacetylases, results in down-regulation of HoxA9 expression
trichostatin-A
-
specific HDAC inhibitor
trichostatin-A
specific HDAC inhibitor; specific HDAC inhibitor; specific HDAC inhibitor
tubacin
-
HDAC6-selective inhibitor
Valproic acid
-
Valproic acid
-
treatment causes hyperacetylation of histones in cultured cells and activates transcription from diverse exogenous and endogenous promoters
Valproic acid
Depakene, Convulex
vorinostat
-
SAHA
additional information
enzyme binding mechanisms, overview
-
additional information
enzyme is part of a high molecular weight complex insensitive to trichostatin A
-
additional information
enzyme is part of a high molecular weight complex insensitive to trichostatin A
-
additional information
-
in phosphate buffer, the presence of NaCl is inhibitory
-
additional information
isoform HDAC10 is resistant to inhibitors trapoxin B and sodium butyrate
-
additional information
-
when A-549 cells are stretched for 24 h cytoplasmic HDAC activity is decreased
-
additional information
-
nitration of distinct tyrosine residues; nitrative/oxidative stress reduce HDAC2 expression via nitration of distinct tyrosine residues. Peroxynitrite, hydrogen peroxide and cigarette smoke-conditioned medium reduce HDAC2 expression in A549 epithelial cells in vitro. This reduction is due to increased proteasomal degradation following ubiquitination rather than reduction of mRNA expression or stability
-
additional information
nitration of distinct tyrosine residues; nitrative/oxidative stress reduce HDAC2 expression via nitration of distinct tyrosine residues. Peroxynitrite, hydrogen peroxide and cigarette smoke-conditioned medium reduce HDAC2 expression in A549 epithelial cells in vitro. This reduction is due to increased proteasomal degradation following ubiquitination rather than reduction of mRNA expression or stability
-
additional information
HDAC is not inhibited by isovaleric acid, L-valine, sodium lactate, succinic acid, citric acid, benzylic acid, hippuric acid, antranilic acid (2-aminobenzoic acid), alpha-hydroxyacetonaphthone, and kojic acid
-
additional information
-
HDAC is not inhibited by isovaleric acid, L-valine, sodium lactate, succinic acid, citric acid, benzylic acid, hippuric acid, antranilic acid (2-aminobenzoic acid), alpha-hydroxyacetonaphthone, and kojic acid
-
additional information
methylselenocysteine and selenomethionine have little or no inhibitory activity up to 2 mM
-
additional information
-
methylselenocysteine and selenomethionine have little or no inhibitory activity up to 2 mM
-
additional information
-
3-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid shows no inhibition of HDAC1 at 0.01 mM, 2,2,2-trifluoro-1-[5-(pyridin-2-yl)thiophen-2-yl]ethanone is inactive against HDAC6, 2,2,2-trifluoro-1-[5-(1H-indol-5-yl)thiophen-2-yl]ethanone is essentially inactive against HDAC1 and 4
-
additional information
-
HDAC10 is not inhibited by SK7068, MS275, and oxamflatin
-
additional information
-
presence of 5-6 carbon units between the Zn2+ binding group and the 1,3,4-thiadiazole ring is optimal for inhibitory potency
-
additional information
enzyme binding mechanisms, overview; enzyme binding mechanisms, overview; enzyme binding mechanisms, overview
-
additional information
enzyme binding mechanisms, overview; enzyme binding mechanisms, overview; enzyme binding mechanisms, overview
-
additional information
enzyme binding mechanisms, overview; enzyme binding mechanisms, overview; enzyme binding mechanisms, overview
-
additional information
-
enzyme binding mechanisms, overview; enzyme binding mechanisms, overview; enzyme binding mechanisms, overview
-
additional information
pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response, structure-activity and structure-property relationships for trans-3,4-disubstituted pyrrolidine inhibitors, overview. No inhibition by (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-hydroxyethyl)pyrrolidine-3-carboxamide and (3R)-4-{4-[(1E)-3-(2-aminoanilino)-3-oxoprop-1-en-1-yl]phenyl}-N-(4-chlorophenyl)-1-(2-hydroxy-2-methylpropyl)pyrrolidine-3-carboxamide
-
additional information
determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes; determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes; determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes
-
additional information
determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes; determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes; determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes
-
additional information
determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes; determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes; determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes
-
additional information
series of HDAC inhibitors, using 1,2,4-oxadiazole-containing as the cap group, are synthesized and evaluated in vitro, inhibitory effects and inhibition of diverse cancer cells, overview. Pharmacokinetic studies. Most HDAC inhibitors always have three parts: a cap group used as a selective vector, a ZBG group to bind with the Zn2+ ion, and a linker region that traditionally allows the ZBG group stretch into the catalytic binding; series of HDAC inhibitors, using 1,2,4-oxadiazole-containing as the cap group, are synthesized and evaluated in vitro, inhibitory effects and inhibition of diverse cancer cells, overview. Pharmacokinetic studies. Most HDAC inhibitors always have three parts: a cap group used as a selective vector, a ZBG group to bind with the Zn2+ ion, and a linker region that traditionally allows the ZBG group stretch into the catalytic binding
-
additional information
series of HDAC inhibitors, using 1,2,4-oxadiazole-containing as the cap group, are synthesized and evaluated in vitro, inhibitory effects and inhibition of diverse cancer cells, overview. Pharmacokinetic studies. Most HDAC inhibitors always have three parts: a cap group used as a selective vector, a ZBG group to bind with the Zn2+ ion, and a linker region that traditionally allows the ZBG group stretch into the catalytic binding; series of HDAC inhibitors, using 1,2,4-oxadiazole-containing as the cap group, are synthesized and evaluated in vitro, inhibitory effects and inhibition of diverse cancer cells, overview. Pharmacokinetic studies. Most HDAC inhibitors always have three parts: a cap group used as a selective vector, a ZBG group to bind with the Zn2+ ion, and a linker region that traditionally allows the ZBG group stretch into the catalytic binding
-
additional information
-
series of HDAC inhibitors, using 1,2,4-oxadiazole-containing as the cap group, are synthesized and evaluated in vitro, inhibitory effects and inhibition of diverse cancer cells, overview. Pharmacokinetic studies. Most HDAC inhibitors always have three parts: a cap group used as a selective vector, a ZBG group to bind with the Zn2+ ion, and a linker region that traditionally allows the ZBG group stretch into the catalytic binding; series of HDAC inhibitors, using 1,2,4-oxadiazole-containing as the cap group, are synthesized and evaluated in vitro, inhibitory effects and inhibition of diverse cancer cells, overview. Pharmacokinetic studies. Most HDAC inhibitors always have three parts: a cap group used as a selective vector, a ZBG group to bind with the Zn2+ ion, and a linker region that traditionally allows the ZBG group stretch into the catalytic binding
-
additional information
pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response, structure-activity and structure-property relationships for trans-3,4-disubstituted pyrrolidine inhibitors, overview
-
additional information
-
pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response, structure-activity and structure-property relationships for trans-3,4-disubstituted pyrrolidine inhibitors, overview
-
additional information
-
the CDK-related kinase 3-associated HDAC activities are sensitive to the class I/II HDAC inhibitor trichostatin A and to the sirtuin inhibitor nicotinamide
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000168 - 0.0137
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
0.00088
(2E)-3-[1,2-bis(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.00041
(2E)-3-[1-benzyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.0012
(2E)-3-[1-benzyl-2-(2-phenylethyl)-1H-benzimidazol-6-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.00022
(2E)-3-[1-ethyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.000052
(2E)-3-[1-[2-(diethylamino)ethyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.000041
(2E)-3-[1-[3-(dimethylamino)-2,2-dimethylpropyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.00019
(2E)-3-[1-[3-(dimethylamino)propyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.00016
(2E)-3-[1-[4-(dimethylamino)butyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.0032
(2E)-3-[2-cyclohexyl-1-(3-hydroxypropyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.00017
(2E)-3-[2-[(benzyloxy)methyl]-1-(3-hydroxypropyl)-1H-benzimidazol-5-yl]-N-hydroxyprop-2-enamide
Homo sapiens
-
-
0.000045
(2E)-3-[4-([[2-(3a,7a-dihydro-1H-indol-3-yl)ethyl](2-hydroxyethyl)amino]methyl)phenyl]-N-hydroxyprop-2-enamide
Homo sapiens
pH and temperature not specified in the publication
0.1
(2E)-N-(2-aminophenyl)-3-[2-(2-phenylethyl)-1-(pyridin-2-ylmethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
larger than 0.10
0.00027
(2E)-N-hydroxy-3-[1-(2-morpholin-4-ylethyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.0011
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.0017
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(1-methylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.0001
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-methylpropyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00017
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00008
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-phenylpropyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00053
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-octyl-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.0019
(2E)-N-hydroxy-3-[1-(3-hydroxypropyl)-2-thiophen-3-yl-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00021
(2E)-N-hydroxy-3-[1-(3-methoxypropyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00025
(2E)-N-hydroxy-3-[1-(3-morpholin-4-ylpropyl)-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00026
(2E)-N-hydroxy-3-[1-methyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00016
(2E)-N-hydroxy-3-[1-[3-(1H-imidazol-1-yl)propyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.0002
(2E)-N-hydroxy-3-[1-[3-(2-oxopyrrolidin-1-yl)propyl]-2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.000026
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(2-piperidin-1-ylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.000035
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(2-pyrrolidin-1-ylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.000047
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00031
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(3-pyrrolidin-1-ylpropyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00025
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(pyridin-2-ylmethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00017
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1-propyl-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00017
(2E)-N-hydroxy-3-[2-(2-phenylethyl)-1H-benzimidazol-5-yl]prop-2-enamide
Homo sapiens
-
-
0.00093
(2E)-N-hydroxy-3-[2-[(4-methoxyphenyl)sulfonyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide
Homo sapiens
-
isoform HDAC1, pH not specified in the publication, temperature not specified in the publication
0.000016
(2E)-N-hydroxy-3-[2-[2-(1H-indol-3-yl)ethyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide
Homo sapiens
-
isoform HDAC1, pH not specified in the publication, temperature not specified in the publication
0.000026
(2E)-N-hydroxy-3-[2-[2-(2-methyl-1H-indol-3-yl)ethyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide
Homo sapiens
-
isoform HDAC1, pH not specified in the publication, temperature not specified in the publication
0.000078
(2E)-N-hydroxy-3-[2-[2-(pyrazolo[1,5-a]pyridin-3-yl)ethyl]-2,3-dihydro-1H-isoindol-5-yl]prop-2-enamide
Homo sapiens
-
isoform HDAC1, pH not specified in the publication, temperature not specified in the publication
0.00002 - 0.0043
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
0.000467 - 0.00573
(2R)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
4 - 8.1
(2S)-2-(acetylamino)-3-[3-[(2S)-2-[[(2S)-2-ammonio-7-(hydroxyamino)-7-oxoheptanoyl]amino]-3-methoxy-3-oxopropyl]phenyl]propanoate
0.00014
(2S)-8-oxo-2-[(3-piperidin-1-ylpropanoyl)amino]-N-quinolin-3-ylnonanamide
Homo sapiens
-
HDAC1
0.00143 - 0.00595
(2S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
0.00011 - 0.013
(3S,15R,20aS)-15-methyl-3-[(1E)-4-sulfanylbut-1-en-1-yl]-3,4,6,7,14,15,18,19,20,20a-decahydro-1H,5H,16H-11,8:15,12-di(azeno)pyrrolo[2,1-c][1,8,12,4,15]oxadithiadiazacyclooctadecine-1,5,16-trione
0.0003 - 0.01
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
0.000025 - 0.01
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
0.00002 - 0.01
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
0.000012 - 0.01
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
0.00027 - 0.03
(4E)-N-(2-aminophenyl)-5-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]pent-4-enamide
0.03
(4Z)-6-[(5R,8S,11R)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-4-enoic acid
Homo sapiens
larger than 0.030
0.014 - 0.03
(5E)-N-(2-aminophenyl)-6-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-5-enamide
0.0000012 - 0.000049
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
0.00000032 - 0.000029
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3-thia-7,14,20,21-tetraazatricyclo[14.3.1.1-2,5]henicosa-1(20),2(21),16,18-tetraene-6,9,13-trione
0.0000019 - 0.00013
(5R,8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
0.0012 - 0.0031
(5S,8R,11R)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
0.00000069 - 0.000045
(5S,8S,11S,5'S,8'S,11'S)-11,11'-[disulfanediyldi(1E)but-1-ene-4,1-diyl]bis[5-methyl-8-(1-methylethyl)-3,10,17-trioxa-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione]
0.000077 - 0.03
(8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),4,16(19)-tetraene-6,9,13-trione
547.3
(E)-3-(2-(((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)pyrimidin-5-yl)-N-hydroxyacrylamide
Homo sapiens
pH and temperature not specified in the publication
0.000035 - 0.000086
(E)-3-[3-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]phenyl]-N-hydroxyacrylamide
292.5
(E)-N-hydroxy-3-(2-(methyl((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidin-5-yl)acrylamide
Homo sapiens
pH and temperature not specified in the publication
0.00016
(E)-N1-hydroxy-N5-(5-styryl-1,3,4-thiadiazol-2-yl)glutaramide
Homo sapiens
-
HDAC from HeLa cell nucleus extracts, mainly including HDAC1 and HDAC2, 37°C, pH not specified in the publication
0.00557
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00106
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(naphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00362
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-m-tolyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00413
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-o-tolyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00382
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-p-tolyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00354
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-pentyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00407
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-phenethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00821
(S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.05
(S)-benzyl 3-(biphenyl-4-ylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
IC50 above 0.05 mM, in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00058
(S)-benzyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.05
(S)-benzyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
IC50 above 0.05 mM, in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00339
(S)-N-(2,4-dimethylphenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00334
(S)-N-(3-chloro-4-fluorophenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.0032
(S)-N-(3-chlorophenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00323
(S)-N-(4-fluorophenyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00221
(S)-N-(biphenyl-4-yl)-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.0051
(S)-N-benzyl-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00577
(S)-N-hexyl-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.01217
(S)-N-tert -butyl-7-(2-(hydroxyamino)-2-oxoethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00378
(S)-tert-butyl 3-(2,4-dimethylphenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00155
(S)-tert-butyl 3-(3-chloro-4-fluorophenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00117
(S)-tert-butyl 3-(3-chlorophenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00256
(S)-tert-butyl 3-(4-fluorophenylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00341
(S)-tert-butyl 3-(benzylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00198
(S)-tert-butyl 3-(biphenyl-4-ylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00442
(S)-tert-butyl 3-(hexylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00458
(S)-tert-butyl 3-(tert-butylcarbamoyl)-7-(2-(hydroxyamino)-2-oxoethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.001
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(4-methoxyphenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00177
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(mtolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00425
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(naphthalen-1-ylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.004
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(o-tolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00165
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(p-tolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00302
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(pentylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00267
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.00129
(S)-tert-butyl 7-(2-(hydroxyamino)-2-oxoethoxy)-3-(phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
Homo sapiens
in 15 mM Tris-HCl, pH 8.0, at 37°C
0.000055
1-methyl-N-[(1S)-7-oxo-1-[(4-phenyl-1,3-thiazol-2-yl)carbamoyl]octyl]piperidine-2-carboxamide
Homo sapiens
-
HDAC1
0.000037 - 0.01
1-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)thiophen-2-yl]-2,2,2-trifluoroethanone
0.000029 - 0.072
1-[5-(4-acetylphenyl)thiophen-2-yl]-2,2,2-trifluoroethanone
0.098
15-deoxy-DELTA12,14-prostaglandin J2-biotin
Homo sapiens
-
recombinant HDAC3 in complex with CoR1, pH and temperature not specified in the publication
0.00013 - 0.0037
2,2,2-trifluoro-1-(2-phenyl-1,3-thiazol-5-yl)ethanone
0.0019 - 0.01
2,2,2-trifluoro-1-(4-phenylthiophen-2-yl)ethanone
0.00017 - 0.02
2,2,2-trifluoro-1-(5-phenylthiophen-2-yl)ethanone
0.000024 - 0.0027
2,2,2-trifluoro-1-(5-[3-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
0.00003 - 0.0022
2,2,2-trifluoro-1-(5-[3-[(propylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
0.000035 - 0.0039
2,2,2-trifluoro-1-(5-[3-[(thiophen-2-ylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
0.005 - 0.01
2,2,2-trifluoro-1-[5-(1H-indol-5-yl)thiophen-2-yl]ethanone
0.0063 - 0.01
2,2,2-trifluoro-1-[5-(2-methoxyphenyl)thiophen-2-yl]ethanone
0.0031 - 0.01
2,2,2-trifluoro-1-[5-(3-methoxyphenyl)thiophen-2-yl]ethanone
0.00006 - 0.0066
2,2,2-trifluoro-1-[5-(3-[[(4-fluorobenzyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl)thiophen-2-yl]ethanone
0.00011 - 0.001
2,2,2-trifluoro-1-[5-(4-methoxyphenyl)thiophen-2-yl]ethanone
0.00054 - 0.001
2,2,2-trifluoro-1-[5-(pyridin-2-yl)thiophen-2-yl]ethanone
0.000015 - 0.00091
2,2,2-trifluoro-1-[5-(quinoxalin-6-yl)thiophen-2-yl]ethanone
34.3
2-(((3-(1-(2,4-difluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
115.7
2-(((3-(1-(2-chloro-4-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
48.3
2-(((3-(1-(2-chlorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
98.6
2-(((3-(1-(2-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
116.6
2-(((3-(1-(4-cyanobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
22
2-(((3-(1-(4-fluorobenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
27.6
2-(((3-(1-benzylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-N-hydroxypyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000026 - 0.01
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)nonyl]acetamide
0.000059 - 0.01
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide
0.198
2-[(methylsulfonyl)sulfanyl]ethanaminium bromide
Homo sapiens
-
-
0.0096
2-[(methylsulfonyl)sulfanyl]ethyl 2-propylpentanoate
Homo sapiens
-
-
0.00007 - 0.0128
3-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
0.0023
3-[5-[(1E)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]-2-(2-phenylethyl)-1H-benzimidazol-1-yl]propanoic acid
Homo sapiens
-
-
0.00023 - 0.0063
3-[5-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]furan-2-yl]-N-hydroxy-acrylamide
0.0564
4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-propylpentanoate
Homo sapiens
-
-
0.133
4-benzoylbutyric hydroxamic acid
Rattus norvegicus
-
-
0.14
4-hydroxy-2-nonenal
Homo sapiens
-
recombinant HDAC3 in complex with CoR1, pH and temperature not specified in the publication
0.000027 - 0.074
4-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
0.000041 - 0.0027
4-[5-(trifluoroacetyl)thiophen-2-yl]benzonitrile
0.04316
4-[[(2E)-2-(4-chlorobenzylidene)hydrazinyl]carbonothioyl]-N-hydroxypiperazine-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00045
5-(4-hydroxyphenyl)-3H-1,2-dithiol-3-thione
Homo sapiens
-
ADTOH
0.005
5-phenylvaleric hydroxamic acid
Rattus norvegicus
-
-
0.00037
6-mercapto-N-phenylhexanamide
Homo sapiens
37°C
0.00039
6-[(1-(mercaptomethyl)vinyl)amino]-N-phenylhexanamide
Homo sapiens
37°C
0.000059
6-[(2E)-2-[(2-bromo-4-hydroxy-5-methoxyphenyl)methylidene]hydrazino]-N-hydroxy-6-oxohexanamide
Plasmodium falciparum
-
0.000106
6-[(2E)-2-[(2-bromo-4-hydroxyphenyl)methylidene]hydrazino]-N-hydroxy-6-oxohexanamide
Plasmodium falciparum
-
0.000089
6-[(2E)-2-[(2-bromo-5-hydroxyphenyl)methylidene]hydrazino]-N-hydroxy-6-oxohexanamide
Plasmodium falciparum
-
0.0001 - 0.01
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
0.00007
6-[(9H-fluoren-3-ylmethyl)(3-phenoxybenzyl)amino]-N-hydroxyhexanamide
Homo sapiens
-
HDAC activity in HeLa nuclear cell extracts, 25°C, pH 8.0
0.00017
6-[(biphenyl-4-ylmethyl)[4-[(4-bromobenzyl)oxy]benzyl]amino]-N-hydroxyhexanamide
Homo sapiens
-
HDAC activity in HeLa nuclear cell extracts, 25°C, pH 8.0
0.0003159
6-[4-(2,6-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide
Homo sapiens
-
-
0.0001626
6-[4-(biphenyl-2-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide
Homo sapiens
-
-
0.0000019
6-[4-(biphenyl-3-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide
Homo sapiens
-
-
0.0000524
6-[4-(biphenyl-4-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyhexanamide
Homo sapiens
-
-
0.00018
6-[[4-[(4-bromobenzyl)oxy]benzyl](9H-fluoren-3-ylmethyl)amino]-N-hydroxyhexanamide
Homo sapiens
-
HDAC activity in HeLa nuclear cell extracts, 25°C, pH 8.0
0.0000043
6-{4-[4-(dimethylamino)phenyl]-1H-1,2,3-triazol-1-yl}-N-hydroxyhexanamide
Homo sapiens
-
-
0.00017
7-mercapto-N-(2-phenyl-1,3-thiazol-5-yl)heptanamide
Homo sapiens
37°C
0.00021
7-mercapto-N-(3-phenoxyphenyl)heptanamide
Homo sapiens
37°C
0.00021
7-mercapto-N-phenylheptanamide
Homo sapiens
37°C
0.00011
7-mercapto-N-pyridin-3-ylheptanamide
Homo sapiens
37°C
0.000072
7-mercapto-N-quinolin-3-ylheptanamide
Homo sapiens
37°C
0.000059
7-[(2E)-2-[(2-bromo-4-hydroxy-5-methoxyphenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
Plasmodium falciparum
-
0.000049
7-[(2E)-2-[(2-bromo-5-hydroxyphenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
Plasmodium falciparum
-
0.000022
7-[(2E)-2-[(2-bromo-5-methoxyphenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
Plasmodium falciparum
-
0.000037
7-[(2E)-2-[(2-bromophenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
Plasmodium falciparum
-
0.000036
7-[(2E)-2-[(2-bromopyridin-3-yl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
Plasmodium falciparum
-
0.00009
7-[(2E)-2-[(2-chlorophenyl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
Plasmodium falciparum
-
0.00002
7-[(2E)-2-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
Plasmodium falciparum
-
0.000037
7-[(2E)-2-[[4-(dimethylamino)-2-hydroxyphenyl]methylidene]hydrazino]-N-hydroxy-7-oxoheptanamide
Plasmodium falciparum
-
0.0000054
7-[4-(biphenyl-3-yl)-1H-1,2,3-triazol-1-yl]-N-hydroxyheptanamide
Homo sapiens
-
-
0.0001061
7-{4-[4-(dimethylamino)phenyl]-1H-1,2,3-triazol-1-yl}-N-hydroxyheptanamide
Homo sapiens
-
-
0.00011
8-[(2E)-2-[(2,5-dihydroxyphenyl)methylidene]hydrazino]-N-hydroxy-8-oxooctanamide
Plasmodium falciparum
-
0.0000007 - 0.01
apicidin
0.02
beta-methylselenopyruvate
Homo sapiens
HDAC8, at 37°C, pH not specified in the publication
2.54
caffeic acid
Homo sapiens
pH and temperature not specified in the publication
0.375
chlorogenic acid
Homo sapiens
pH and temperature not specified in the publication
0.115
curcumin
Homo sapiens
pH and temperature not specified in the publication
0.0000018
LBH-589
Plasmodium falciparum
-
0.000046 - 0.231
methyl (3R,6R,9R)-9-(acetylamino)-6-[6-(hydroxyamino)-6-oxohexyl]-5,8-dioxo-4,7-diazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3-carboxylate
0.000167 - 0.000174
methyl N-[(2S)-2-[(N-acetyl-L-alanyl)amino]-7-(hydroxyamino)-7-oxoheptanoyl]-L-phenylalaninate
0.00967 - 0.033
N-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
0.00152 - 0.0142
N-(4-amino-4'-chloro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
0.000045 - 0.0259
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-1H-2-benzopyran-3-carboxamide
0.000072 - 0.033
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-2H-1-benzopyran-3-carboxamide
0.000123 - 0.00149
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3-oxabicyclo[3.1.0]hexane-6-carboxamide
0.00122 - 0.0198
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
0.00002 - 0.00109
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
0.000119 - 0.00385
N-(4-amino[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
0.000079
N-(6-mercaptohexyl)-1-benzofuran-2-carboxamide
Homo sapiens
37°C
0.0001
N-(6-mercaptohexyl)-1H-indole-2-carboxamide
Homo sapiens
37°C
0.000085
N-(6-mercaptohexyl)-2-naphthamide
Homo sapiens
37°C
0.00036
N-(6-mercaptohexyl)benzamide
Homo sapiens
37°C
0.0000097
N-(8,8,8-trifluoro-7-oxooctyl)benzamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
-
0.000075
N-biphenyl-3-yl-7-mercaptoheptanamide
Homo sapiens
37°C
0.0033
N-hydroxy-1-(3-hydroxypropyl)-2-(2-phenylethyl)-1H-benzimidazole-5-carboxamide
Homo sapiens
-
-
47.3
N-hydroxy-2-(methyl((3-(1-(3-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
207
N-hydroxy-2-(methyl((3-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
12.1
N-hydroxy-2-(methyl((3-(1-(4-methylbenzyl)piperidin-4-yl)-1,2,4-oxadiazol-5-yl)methyl)amino)pyrimidine-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0013
N-hydroxy-2-[1-methyl-2-(2-phenylethyl)-1H-benzimidazol-5-yl]cyclopropanecarboxamide
Homo sapiens
-
-
0.01
N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-methylpropyl)-1H-benzimidazol-5-yl]propanamide
Homo sapiens
-
larger than 0.010
0.00017
N-hydroxy-3-[2-(2-phenylethyl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazol-5-yl]propanamide
Homo sapiens
-
-
0.00002
N-hydroxy-3-[2-[(2-methyl-1H-indol-3-yl)acetyl]-2,3-dihydro-1H-isoindol-5-yl]propanamide
Homo sapiens
-
isoform HDAC1, pH not specified in the publication, temperature not specified in the publication
0.000044 - 0.000175
N-hydroxy-4-(methyl[(5-pyridin-2-yl-2-thienyl)sulfonyl]amino)benzamide
0.03367
N-hydroxy-4-[[(2E)-2-(2-hydroxybenzylidene)hydrazinyl]carbonothioyl]piperazine-1-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00011
N-hydroxy-5-(4-phenyl-1H-1,2,3-triazol-1-yl)pentanamide
Homo sapiens
-
-
0.0000142
N-hydroxy-6-(4-phenyl-1H-1,2,3-triazol-1-yl)hexanamide
Homo sapiens
-
-
0.0000002 - 0.01
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
0.0000006 - 0.01
N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide
0.000076
N-hydroxy-6-[4-(2-methoxyphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0000139
N-hydroxy-6-[4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0000174 - 0.0000319
N-hydroxy-6-[4-(3-methylphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
0.0000021
N-hydroxy-6-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0000434
N-hydroxy-6-[4-(4-methylphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0000018
N-hydroxy-6-[4-(6-methoxynaphthalen-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0000676
N-hydroxy-6-[4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0002872
N-hydroxy-6-[4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0001125
N-hydroxy-6-[4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0000021
N-hydroxy-6-[4-(quinolin-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0001515
N-hydroxy-6-[4-(quinolin-7-yl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0000317
N-hydroxy-6-[4-(thiophen-2-yl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0000023
N-hydroxy-6-{4-[4-(pyridin-4-yl)phenyl]-1H-1,2,3-triazol-1-yl}hexanamide
Homo sapiens
-
-
0.0000096
N-hydroxy-7-(4-phenyl-1H-1,2,3-triazol-1-yl)heptanamide
Homo sapiens
-
-
0.000041
N-hydroxy-7-[(2E)-2-[(2-hydroxynaphthalen-1-yl)methylidene]hydrazino]-7-oxoheptanamide
Plasmodium falciparum
-
0.000059
N-hydroxy-7-[(2E)-2-[(3-hydroxyphenyl)methylidene]hydrazino]-7-oxoheptanamide
Plasmodium falciparum
-
0.000015
N-hydroxy-7-[(2E)-2-[[4-(1H-imidazol-1-yl)phenyl]methylidene]hydrazino]-7-oxoheptanamide
Plasmodium falciparum
-
0.0000153
N-hydroxy-7-[4-(6-methoxynaphthalen-2-yl)-1H-1,2,3-triazol-1-yl]heptanamide
Homo sapiens
-
-
0.0000239
N-hydroxy-7-[4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl]heptanamide
Homo sapiens
-
-
0.0000166
N-hydroxy-7-{4-[4-(pyridin-4-yl)phenyl]-1H-1,2,3-triazol-1-yl}heptanamide
Homo sapiens
-
-
0.000043
N-hydroxy-8-oxo-8-[(2E)-2-[(2,4,6-trihydroxyphenyl)methylidene]hydrazino]octanamide
Plasmodium falciparum
-
0.000089 - 0.00058
N-methyl-N-(quinoxalin-6-ylmethyl)-5-(trifluoroacetyl)thiophene-2-carboxamide
0.00067 - 0.01
N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
0.00067 - 0.0016
N-[(2E)-3-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]prop-2-en-1-yl]-2-sulfanylacetamide
0.00024 - 0.0019
N-[(3E)-4-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-en-1-yl]-2-sulfanylacetamide
0.0000621
N-[1,1,2,2,3,3,4,4,5,5,6,6-dodecafluoro-7-(hydroxyamino)-7-oxoheptyl]benzamide
Pseudomonas aeruginosa
pH and temperature not specified in the publication
0.00645 - 0.0208
N-[2-amino-5-(pyridin-3-yl)phenyl]oxane-4-carboxamide
0.00142 - 0.033
N-[2-amino-5-(pyridin-4-yl)phenyl]oxane-4-carboxamide
0.0267 - 0.033
N-[4-amino-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxane-4-carboxamide
0.00022
N1-(5-benzyl-1,3,4-thiadiazol-2-yl)-N7-hydroxyheptanediamide
Homo sapiens
-
HDAC from HeLa cell nucleus extracts, mainly including HDAC1 and HDAC2, 37°C, pH not specified in the publication
0.00026
N1-(5-benzyl-1,3,4-thiadiazol-2-yl)-N8-hydroxyoctanediamide
Homo sapiens
-
HDAC from HeLa cell nucleus extracts, mainly including HDAC1 and HDAC2, 37°C, pH not specified in the publication
0.000089
N1-hydroxy-N7-(5-phenyl-1,3,4-thiadiazol-2-yl)heptanediamide
Homo sapiens
-
HDAC from HeLa cell nucleus extracts, mainly including HDAC1 and HDAC2, 37°C, pH not specified in the publication
0.00027
N1-hydroxy-N8-(5-phenyl-1,3,4-thiadiazol-2-yl)octanediamide
Homo sapiens
-
HDAC from HeLa cell nucleus extracts, mainly including HDAC1 and HDAC2, 37°C, pH not specified in the publication
0.00034
N1-methyl-2-oxo-N9-phenylnonanediamide
Homo sapiens
37°C
0.0026 - 0.098
oxamflatin
0.000185 - 0.01
pyridin-3-ylmethyl (4-[[(2-aminophenyl)amino]carbonyl]benzyl)carbamate
0.102
S-(2-hydroxyethyl) methanesulfonothioate
Homo sapiens
-
-
0.0175
S-[2-[(2-propylpentanoyl)amino]ethyl]methanesulfonothioate
Homo sapiens
-
-
0.013
sodium butyrate
Homo sapiens
-
recombinant HDAC3 in complex with CoR1, pH and temperature not specified in the publication
0.01
splitomicin
Plasmodium falciparum
larger than 0.01
0.00001 - 0.113
suberoylanilide hydroxamic acid
0.0000006 - 0.008
trichostatin A
0.4 - 0.995
Valproic acid
0.00003 - 0.01
vorinostat
0.000045
[4-[(E)-[[6-(hydroxyamino)-6-oxohexanoyl]hydrazono]methyl]phenyl]boronic acid
Plasmodium falciparum
-
0.000168
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.000192
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.00145
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.00159
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.00228
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.0137
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00002
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Homo sapiens
mutant H843Y
0.0043
(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Homo sapiens
wild type
0.000467
(2R)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.00129
(2R)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.00573
(2R)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
4
(2S)-2-(acetylamino)-3-[3-[(2S)-2-[[(2S)-2-ammonio-7-(hydroxyamino)-7-oxoheptanoyl]amino]-3-methoxy-3-oxopropyl]phenyl]propanoate
Homo sapiens
-
isoform HDAC1
8.1
(2S)-2-(acetylamino)-3-[3-[(2S)-2-[[(2S)-2-ammonio-7-(hydroxyamino)-7-oxoheptanoyl]amino]-3-methoxy-3-oxopropyl]phenyl]propanoate
Homo sapiens
-
HeLa cell nuclear extract
0.00143
(2S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.00145
(2S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.00595
(2S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00011
(3S,15R,20aS)-15-methyl-3-[(1E)-4-sulfanylbut-1-en-1-yl]-3,4,6,7,14,15,18,19,20,20a-decahydro-1H,5H,16H-11,8:15,12-di(azeno)pyrrolo[2,1-c][1,8,12,4,15]oxadithiadiazacyclooctadecine-1,5,16-trione
Homo sapiens
-
0.00058
(3S,15R,20aS)-15-methyl-3-[(1E)-4-sulfanylbut-1-en-1-yl]-3,4,6,7,14,15,18,19,20,20a-decahydro-1H,5H,16H-11,8:15,12-di(azeno)pyrrolo[2,1-c][1,8,12,4,15]oxadithiadiazacyclooctadecine-1,5,16-trione
Homo sapiens
-
0.0008
(3S,15R,20aS)-15-methyl-3-[(1E)-4-sulfanylbut-1-en-1-yl]-3,4,6,7,14,15,18,19,20,20a-decahydro-1H,5H,16H-11,8:15,12-di(azeno)pyrrolo[2,1-c][1,8,12,4,15]oxadithiadiazacyclooctadecine-1,5,16-trione
Homo sapiens
-
0.013
(3S,15R,20aS)-15-methyl-3-[(1E)-4-sulfanylbut-1-en-1-yl]-3,4,6,7,14,15,18,19,20,20a-decahydro-1H,5H,16H-11,8:15,12-di(azeno)pyrrolo[2,1-c][1,8,12,4,15]oxadithiadiazacyclooctadecine-1,5,16-trione
Homo sapiens
-
0.0003
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC1
0.0004
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC10
0.0004
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC2
0.0004
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC9
0.0015
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC3
0.0028
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC5
0.01
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC4, larger than 0.010
0.01
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC6, larger than 0.010
0.01
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC7, larger than 0.010
0.01
(3S,6S,10S,14S)-3-(1H-indol-3-ylmethyl)-10-methyl-14-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,11-tetraazacyclotetradecane-2,5,8,12-tetrone
Homo sapiens
-
HDAC8, larger than 0.010
0.000025
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC9
0.000028
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC10
0.00004
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC2
0.00005
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC1
0.00006
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC5
0.00055
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC3
0.002
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC8
0.01
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC4, larger than 0.010
0.01
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC6, larger than 0.010
0.01
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9,10-dimethyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC7, larger than 0.010
0.00002
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC10
0.00003
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC2
0.00003
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC9
0.000035
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC1
0.00007
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC5
0.00015
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC3
0.0022
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC8
0.01
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC4, larger than 0.010
0.01
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC6, larger than 0.010
0.01
(3S,6S,9S,13S)-3-(1H-indol-3-ylmethyl)-9-methyl-13-(2-methylpropyl)-6-(6-oxooctyl)-1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetrone
Homo sapiens
-
HDAC7, larger than 0.010
0.000012
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC1
0.000015
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC10
0.000022
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC9
0.00004
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC2
0.00005
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC5
0.00028
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC3
0.0015
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC8
0.01
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC4, larger than 0.010
0.01
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC6, larger than 0.010
0.01
(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-3-(6-oxooctyl)decahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecine-1,4,7,11(8H)-tetrone
Homo sapiens
-
HDAC7, larger than 0.010
0.00027
(4E)-N-(2-aminophenyl)-5-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]pent-4-enamide
Homo sapiens
-
0.0041
(4E)-N-(2-aminophenyl)-5-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]pent-4-enamide
Homo sapiens
-
0.03
(4E)-N-(2-aminophenyl)-5-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]pent-4-enamide
Homo sapiens
larger than 0.030
0.014
(5E)-N-(2-aminophenyl)-6-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-5-enamide
Homo sapiens
-
0.023
(5E)-N-(2-aminophenyl)-6-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-5-enamide
Homo sapiens
-
0.029
(5E)-N-(2-aminophenyl)-6-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-5-enamide
Homo sapiens
-
0.03
(5E)-N-(2-aminophenyl)-6-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]hex-5-enamide
Homo sapiens
larger than 0.030
0.0000012
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.0000034
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.0000035
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.000049
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.00000032
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3-thia-7,14,20,21-tetraazatricyclo[14.3.1.1-2,5]henicosa-1(20),2(21),16,18-tetraene-6,9,13-trione
Homo sapiens
-
0.00000086
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3-thia-7,14,20,21-tetraazatricyclo[14.3.1.1-2,5]henicosa-1(20),2(21),16,18-tetraene-6,9,13-trione
Homo sapiens
-
0.0000011
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3-thia-7,14,20,21-tetraazatricyclo[14.3.1.1-2,5]henicosa-1(20),2(21),16,18-tetraene-6,9,13-trione
Homo sapiens
-
0.000029
(5R,8S,11S)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3-thia-7,14,20,21-tetraazatricyclo[14.3.1.1-2,5]henicosa-1(20),2(21),16,18-tetraene-6,9,13-trione
Homo sapiens
-
0.0000019
(5R,8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.0000038
(5R,8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.0000048
(5R,8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.00013
(5R,8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.0012
(5S,8R,11R)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.0019
(5S,8R,11R)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.0022
(5S,8R,11R)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.0031
(5S,8R,11R)-5-methyl-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione
Homo sapiens
-
0.00000069
(5S,8S,11S,5'S,8'S,11'S)-11,11'-[disulfanediyldi(1E)but-1-ene-4,1-diyl]bis[5-methyl-8-(1-methylethyl)-3,10,17-trioxa-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione]
Homo sapiens
-
0.0000015
(5S,8S,11S,5'S,8'S,11'S)-11,11'-[disulfanediyldi(1E)but-1-ene-4,1-diyl]bis[5-methyl-8-(1-methylethyl)-3,10,17-trioxa-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione]
Homo sapiens
-
0.0000017
(5S,8S,11S,5'S,8'S,11'S)-11,11'-[disulfanediyldi(1E)but-1-ene-4,1-diyl]bis[5-methyl-8-(1-methylethyl)-3,10,17-trioxa-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione]
Homo sapiens
-
0.000045
(5S,8S,11S,5'S,8'S,11'S)-11,11'-[disulfanediyldi(1E)but-1-ene-4,1-diyl]bis[5-methyl-8-(1-methylethyl)-3,10,17-trioxa-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-triene-6,9,13-trione]
Homo sapiens
-
0.000077
(8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),4,16(19)-tetraene-6,9,13-trione
Homo sapiens
-
0.000085
(8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),4,16(19)-tetraene-6,9,13-trione
Homo sapiens
-
0.00012
(8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),4,16(19)-tetraene-6,9,13-trione
Homo sapiens
-
0.03
(8S,11S)-8-(1-methylethyl)-11-[(1E)-4-sulfanylbut-1-en-1-yl]-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),4,16(19)-tetraene-6,9,13-trione
Homo sapiens
larger than 0.030
0.000035
(E)-3-[3-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]phenyl]-N-hydroxyacrylamide
Homo sapiens
-
recombinant HDAC3, pH not specified in the publication, temperature not specified in the publication
0.000047
(E)-3-[3-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]phenyl]-N-hydroxyacrylamide
Homo sapiens
-
recombinant HDAC1, pH not specified in the publication, temperature not specified in the publication
0.000066
(E)-3-[3-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]phenyl]-N-hydroxyacrylamide
Homo sapiens
-
recombinant HDAC6, pH not specified in the publication, temperature not specified in the publication
0.000086
(E)-3-[3-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]phenyl]-N-hydroxyacrylamide
Homo sapiens
-
recombinant HDAC8, pH not specified in the publication, temperature not specified in the publication
0.000037
1-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)thiophen-2-yl]-2,2,2-trifluoroethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.01
1-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)thiophen-2-yl]-2,2,2-trifluoroethanone
Homo sapiens
-
IC50 above 0.01 mM, HDAC1, pH and temperature not specified in the publication
0.01
1-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)thiophen-2-yl]-2,2,2-trifluoroethanone
Homo sapiens
-
IC50 above 0.01 mM, HDAC4, pH and temperature not specified in the publication
0.000029
1-[5-(4-acetylphenyl)thiophen-2-yl]-2,2,2-trifluoroethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.01
1-[5-(4-acetylphenyl)thiophen-2-yl]-2,2,2-trifluoroethanone
Homo sapiens
-
IC50 above 0.01 mM, HDAC1, pH and temperature not specified in the publication
0.072
1-[5-(4-acetylphenyl)thiophen-2-yl]-2,2,2-trifluoroethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.00013
2,2,2-trifluoro-1-(2-phenyl-1,3-thiazol-5-yl)ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.00021
2,2,2-trifluoro-1-(2-phenyl-1,3-thiazol-5-yl)ethanone
Homo sapiens
-
HDAC6 pH and temperature not specified in the publication
0.0037
2,2,2-trifluoro-1-(2-phenyl-1,3-thiazol-5-yl)ethanone
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.0019
2,2,2-trifluoro-1-(4-phenylthiophen-2-yl)ethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.0032
2,2,2-trifluoro-1-(4-phenylthiophen-2-yl)ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.01
2,2,2-trifluoro-1-(4-phenylthiophen-2-yl)ethanone
Homo sapiens
-
IC50 above 0.01 mM, HDAC1, pH and temperature not specified in the publication
0.00017
2,2,2-trifluoro-1-(5-phenylthiophen-2-yl)ethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.0028
2,2,2-trifluoro-1-(5-phenylthiophen-2-yl)ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.02
2,2,2-trifluoro-1-(5-phenylthiophen-2-yl)ethanone
Homo sapiens
-
IC50 above 0.02 mM, HDAC1, pH and temperature not specified in the publication
0.000024
2,2,2-trifluoro-1-(5-[3-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.00023
2,2,2-trifluoro-1-(5-[3-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.0027
2,2,2-trifluoro-1-(5-[3-[(methylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.00003
2,2,2-trifluoro-1-(5-[3-[(propylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.00024
2,2,2-trifluoro-1-(5-[3-[(propylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.0022
2,2,2-trifluoro-1-(5-[3-[(propylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.000035
2,2,2-trifluoro-1-(5-[3-[(thiophen-2-ylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.00052
2,2,2-trifluoro-1-(5-[3-[(thiophen-2-ylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.0039
2,2,2-trifluoro-1-(5-[3-[(thiophen-2-ylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl]thiophen-2-yl)ethanone
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.005
2,2,2-trifluoro-1-[5-(1H-indol-5-yl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.005 mM, HDAC6, pH and temperature not specified in the publication
0.01
2,2,2-trifluoro-1-[5-(1H-indol-5-yl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.01 mM, HDAC1, pH and temperature not specified in the publication
0.01
2,2,2-trifluoro-1-[5-(1H-indol-5-yl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.01 mM, HDAC4, pH and temperature not specified in the publication
0.0063
2,2,2-trifluoro-1-[5-(2-methoxyphenyl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.01
2,2,2-trifluoro-1-[5-(2-methoxyphenyl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.01 mM, HDAC1, pH and temperature not specified in the publication
0.01
2,2,2-trifluoro-1-[5-(2-methoxyphenyl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.01 mM, HDAC4, pH and temperature not specified in the publication
0.0031
2,2,2-trifluoro-1-[5-(3-methoxyphenyl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.0038
2,2,2-trifluoro-1-[5-(3-methoxyphenyl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.01
2,2,2-trifluoro-1-[5-(3-methoxyphenyl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.01 mM, HDAC1, pH and temperature not specified in the publication
0.00006
2,2,2-trifluoro-1-[5-(3-[[(4-fluorobenzyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.0007
2,2,2-trifluoro-1-[5-(3-[[(4-fluorobenzyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.0066
2,2,2-trifluoro-1-[5-(3-[[(4-fluorobenzyl)sulfonyl]methyl]-1,2,4-oxadiazol-5-yl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.00011
2,2,2-trifluoro-1-[5-(4-methoxyphenyl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.001
2,2,2-trifluoro-1-[5-(4-methoxyphenyl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.001 mM, HDAC1, pH and temperature not specified in the publication
0.001
2,2,2-trifluoro-1-[5-(4-methoxyphenyl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.001 mM, HDAC6, pH and temperature not specified in the publication
0.00054
2,2,2-trifluoro-1-[5-(pyridin-2-yl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.001
2,2,2-trifluoro-1-[5-(pyridin-2-yl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.001 mM, HDAC1, pH and temperature not specified in the publication
0.001
2,2,2-trifluoro-1-[5-(pyridin-2-yl)thiophen-2-yl]ethanone
Homo sapiens
-
IC50 above 0.001 mM, HDAC6, pH and temperature not specified in the publication
0.000015
2,2,2-trifluoro-1-[5-(quinoxalin-6-yl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.00016
2,2,2-trifluoro-1-[5-(quinoxalin-6-yl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.00091
2,2,2-trifluoro-1-[5-(quinoxalin-6-yl)thiophen-2-yl]ethanone
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.000026
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)nonyl]acetamide
Homo sapiens
-
HDAC1
0.000048
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)nonyl]acetamide
Homo sapiens
-
HDAC3
0.000059
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)nonyl]acetamide
Homo sapiens
-
HDAC2
0.01
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)nonyl]acetamide
Homo sapiens
-
HDAC5, larger than 0.010
0.01
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)nonyl]acetamide
Homo sapiens
-
HDAC7, larger than 0.010
0.000059
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide
Homo sapiens
-
HDAC1
0.00011
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide
Homo sapiens
-
HDAC2
0.00012
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide
Homo sapiens
-
HDAC3
0.00034
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide
Homo sapiens
-
HDAC6
0.005
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide
Homo sapiens
-
HDAC8, larger than 0.005
0.01
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide
Homo sapiens
-
HDAC5, larger than 0.010
0.01
2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1S)-7-oxo-1-(5-phenyl-1H-imidazol-2-yl)octyl]acetamide
Homo sapiens
-
HDAC7, larger than 0.010
0.00007
3-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.00031
3-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.0128
3-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.00023
3-[5-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]furan-2-yl]-N-hydroxy-acrylamide
Homo sapiens
-
recombinant HDAC8, pH not specified in the publication, temperature not specified in the publication
0.00061
3-[5-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]furan-2-yl]-N-hydroxy-acrylamide
Homo sapiens
-
recombinant HDAC3, pH not specified in the publication, temperature not specified in the publication
0.00063
3-[5-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]furan-2-yl]-N-hydroxy-acrylamide
Homo sapiens
-
recombinant HDAC1, pH not specified in the publication, temperature not specified in the publication
0.0063
3-[5-[4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl]furan-2-yl]-N-hydroxy-acrylamide
Homo sapiens
-
recombinant HDAC6, pH not specified in the publication, temperature not specified in the publication
0.000027
4-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.0025
4-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.074
4-[5-(trifluoroacetyl)thiophen-2-yl]benzoic acid
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.000041
4-[5-(trifluoroacetyl)thiophen-2-yl]benzonitrile
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.00016
4-[5-(trifluoroacetyl)thiophen-2-yl]benzonitrile
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.0027
4-[5-(trifluoroacetyl)thiophen-2-yl]benzonitrile
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.0001
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC1
0.0002
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC2
0.00028
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC10
0.00055
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC9
0.0006
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC3
0.0007
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC5
0.0023
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC6
0.0023
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC8
0.01
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC4, larger than 0.010
0.01
6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanoic acid
Homo sapiens
-
HDAC7, larger than 0.010
0.0000007
apicidin
Homo sapiens
isoform HDAC3
0.000001
apicidin
Plasmodium falciparum
-
0.000002
apicidin
Homo sapiens
isoform HDAC1
0.000015
apicidin
Homo sapiens
-
HDAC9
0.000018
apicidin
Homo sapiens
-
HDAC1
0.00003
apicidin
Homo sapiens
-
HDAC10
0.000035
apicidin
Homo sapiens
-
HDAC2
0.000044
apicidin
Homo sapiens
-
HDAC1
0.00008
apicidin
Homo sapiens
-
HDAC5
0.0001
apicidin
Homo sapiens
-
HDAC3
0.00075
apicidin
Homo sapiens
-
HDAC8
0.001
apicidin
Homo sapiens
isoform HDAC8
0.01
apicidin
Homo sapiens
-
HDAC4, larger than 0.010
0.01
apicidin
Homo sapiens
-
HDAC6, larger than 0.010
0.01
apicidin
Homo sapiens
-
HDAC7, larger than 0.010
0.021
Butyrate
Gallus gallus
-
isoform HD2
0.045
Butyrate
Gallus gallus
-
isoform HD1
0.08
Butyrate
Gallus gallus
-
nuclear matrix form of enzyme
0.35
Butyrate
Homo sapiens
pH 8.0
0.0036
LAQ824
Homo sapiens
mutant H843Y
0.553
LAQ824
Homo sapiens
wild type
0.00013
LBH589
Homo sapiens
mutant H843Y
0.0154
LBH589
Homo sapiens
wild type
0.000046
methyl (3R,6R,9R)-9-(acetylamino)-6-[6-(hydroxyamino)-6-oxohexyl]-5,8-dioxo-4,7-diazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3-carboxylate
Homo sapiens
-
HeLa cell nuclear extract
0.000057
methyl (3R,6R,9R)-9-(acetylamino)-6-[6-(hydroxyamino)-6-oxohexyl]-5,8-dioxo-4,7-diazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3-carboxylate
Homo sapiens
-
isoform HDAC1
0.231
methyl (3R,6R,9R)-9-(acetylamino)-6-[6-(hydroxyamino)-6-oxohexyl]-5,8-dioxo-4,7-diazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3-carboxylate
Homo sapiens
-
isoform HDAC8
0.000167
methyl N-[(2S)-2-[(N-acetyl-L-alanyl)amino]-7-(hydroxyamino)-7-oxoheptanoyl]-L-phenylalaninate
Homo sapiens
-
HeLa cell nuclear extract
0.000174
methyl N-[(2S)-2-[(N-acetyl-L-alanyl)amino]-7-(hydroxyamino)-7-oxoheptanoyl]-L-phenylalaninate
Homo sapiens
-
isoform HDAC1
0.000045
MS-275
Homo sapiens
-
0.00012
MS-275
Homo sapiens
-
HDAC1
0.00013
MS-275
Homo sapiens
-
0.00017
MS-275
Homo sapiens
-
0.00025
MS-275
Homo sapiens
-
HDAC2
0.0004
MS-275
Homo sapiens
-
HDAC3
0.00094
MS-275
Plasmodium falciparum
-
0.01
MS-275
Homo sapiens
-
HDAC5, larger than 0.010
0.01
MS-275
Homo sapiens
-
HDAC6, larger than 0.010
0.01
MS-275
Homo sapiens
-
HDAC7, larger than 0.010
0.01
MS-275
Homo sapiens
-
HDAC8, larger than 0.010
0.03
MS-275
Homo sapiens
larger than 0.030
0.00967
N-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.0123
N-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.033
N-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, above, HDAC3 isozyme
0.00152
N-(4-amino-4'-chloro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.00253
N-(4-amino-4'-chloro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.0142
N-(4-amino-4'-chloro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.000045
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-1H-2-benzopyran-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.000119
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-1H-2-benzopyran-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.0259
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-1H-2-benzopyran-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.000072
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.000156
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.033
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 7.4, 22°C, above, HDAC3 isozyme
0.000123
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3-oxabicyclo[3.1.0]hexane-6-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.000219
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3-oxabicyclo[3.1.0]hexane-6-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.00149
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3-oxabicyclo[3.1.0]hexane-6-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00122
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.00473
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.00559
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.00626
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00656
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.0198
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00002
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.000062
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.00109
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.000119
N-(4-amino[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.000312
N-(4-amino[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.00385
N-(4-amino[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.000044
N-hydroxy-4-(methyl[(5-pyridin-2-yl-2-thienyl)sulfonyl]amino)benzamide
Homo sapiens
isoform HDAC3
0.000086
N-hydroxy-4-(methyl[(5-pyridin-2-yl-2-thienyl)sulfonyl]amino)benzamide
Homo sapiens
isoform HDAC1
0.000175
N-hydroxy-4-(methyl[(5-pyridin-2-yl-2-thienyl)sulfonyl]amino)benzamide
Homo sapiens
isoform HDAC8
0.0000002
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC10
0.0000006
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC9
0.0000015
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC1
0.0000025
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC5
0.000005
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC2
0.000025
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC3
0.00003
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC6
0.00012
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC8
0.01
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC4, larger than 0.010
0.01
N-hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-5-yl]hexanamide
Homo sapiens
-
HDAC7, larger than 0.010
0.0000006
N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide
Homo sapiens
-
HDAC1
0.0000035
N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide
Homo sapiens
-
HDAC2
0.000035
N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide
Homo sapiens
-
HDAC3
0.000035
N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide
Homo sapiens
-
HDAC6
0.00018
N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide
Homo sapiens
-
HDAC8
0.01
N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide
Homo sapiens
-
HDAC4, larger than 0.010
0.01
N-hydroxy-6-[(3S,6S,9S,15aS)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-1,4,7,11-tetraoxotetradecahydro-1H-pyrrolo[1,2-a][1,4,7,10]tetraazacyclotridecin-3-yl]hexanamide
Homo sapiens
-
HDAC7, larger than 0.010
0.0000174
N-hydroxy-6-[4-(3-methylphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.0000319
N-hydroxy-6-[4-(3-methylphenyl)-1H-1,2,3-triazol-1-yl]hexanamide
Homo sapiens
-
-
0.000089
N-methyl-N-(quinoxalin-6-ylmethyl)-5-(trifluoroacetyl)thiophene-2-carboxamide
Homo sapiens
-
HDAC6, pH and temperature not specified in the publication
0.000098
N-methyl-N-(quinoxalin-6-ylmethyl)-5-(trifluoroacetyl)thiophene-2-carboxamide
Homo sapiens
-
HDAC4, pH and temperature not specified in the publication
0.00058
N-methyl-N-(quinoxalin-6-ylmethyl)-5-(trifluoroacetyl)thiophene-2-carboxamide
Homo sapiens
-
HDAC1, pH and temperature not specified in the publication
0.00067
N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
Homo sapiens
-
HDAC1
0.00088
N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
Homo sapiens
-
HDAC2
0.00097
N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
Homo sapiens
-
HDAC6
0.001
N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
Homo sapiens
-
HDAC3
0.01
N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
Homo sapiens
-
HDAC5, larger than 0.010
0.01
N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
Homo sapiens
-
HDAC7, larger than 0.010
0.01
N-[(1S)-1-(6-chloro-1H-benzimidazol-2-yl)-7-oxooctyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
Homo sapiens
-
HDAC8, larger than 0.010
0.00067
N-[(2E)-3-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]prop-2-en-1-yl]-2-sulfanylacetamide
Homo sapiens
-
0.0007
N-[(2E)-3-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]prop-2-en-1-yl]-2-sulfanylacetamide
Homo sapiens
-
0.00096
N-[(2E)-3-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]prop-2-en-1-yl]-2-sulfanylacetamide
Homo sapiens
-
0.0016
N-[(2E)-3-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]prop-2-en-1-yl]-2-sulfanylacetamide
Homo sapiens
-
0.00024
N-[(3E)-4-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-en-1-yl]-2-sulfanylacetamide
Homo sapiens
-
0.001
N-[(3E)-4-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-en-1-yl]-2-sulfanylacetamide
Homo sapiens
-
0.0015
N-[(3E)-4-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-en-1-yl]-2-sulfanylacetamide
Homo sapiens
-
0.0019
N-[(3E)-4-[(5R,8S,11S)-5-methyl-8-(1-methylethyl)-6,9,13-trioxo-10-oxa-3,17-dithia-7,14,19,20-tetraazatricyclo[14.2.1.1-2,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-en-1-yl]-2-sulfanylacetamide
Homo sapiens
-
0.00645
N-[2-amino-5-(pyridin-3-yl)phenyl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.00732
N-[2-amino-5-(pyridin-3-yl)phenyl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.0208
N-[2-amino-5-(pyridin-3-yl)phenyl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00142
N-[2-amino-5-(pyridin-4-yl)phenyl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC2 isozyme
0.00235
N-[2-amino-5-(pyridin-4-yl)phenyl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.033
N-[2-amino-5-(pyridin-4-yl)phenyl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, above, HDAC3 isozyme
0.0267
N-[4-amino-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC1 isozyme
0.033
N-[4-amino-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, above, HDAC2 isozyme
0.033
N-[4-amino-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, above, HDAC3 isozyme
0.0026
oxamflatin
Homo sapiens
mutant H843Y
0.098
oxamflatin
Homo sapiens
wild type
0.000185
pyridin-3-ylmethyl (4-[[(2-aminophenyl)amino]carbonyl]benzyl)carbamate
Homo sapiens
isoform HDAC1
0.000201
pyridin-3-ylmethyl (4-[[(2-aminophenyl)amino]carbonyl]benzyl)carbamate
Homo sapiens
isoform HDAC3
0.01
pyridin-3-ylmethyl (4-[[(2-aminophenyl)amino]carbonyl]benzyl)carbamate
Homo sapiens
isoform HDAC8
0.00001
suberoylanilide hydroxamic acid
Homo sapiens
-
0.000013
suberoylanilide hydroxamic acid
Homo sapiens
-
0.000017
suberoylanilide hydroxamic acid
Homo sapiens
-
0.000026
suberoylanilide hydroxamic acid
Homo sapiens
-
0.000059
suberoylanilide hydroxamic acid
Plasmodium falciparum
-
0.000065
suberoylanilide hydroxamic acid
Homo sapiens
-
-
0.000065
suberoylanilide hydroxamic acid
Candida albicans
-
pH 8.0, 37°C, recombinant enzyme
0.000106
suberoylanilide hydroxamic acid
Homo sapiens
isoform HDAC3
0.00011
suberoylanilide hydroxamic acid
Homo sapiens
-
HeLa cell nuclear extract
0.000112
suberoylanilide hydroxamic acid
Homo sapiens
-
isoform HDAC1
0.000119
suberoylanilide hydroxamic acid
Homo sapiens
isoform HDAC1
0.00015
suberoylanilide hydroxamic acid
Homo sapiens
-
HDAC from HeLa cell nucleus extracts, mainly including HDAC1 and HDAC2, 37°C, pH not specified in the publication
0.00027
suberoylanilide hydroxamic acid
Homo sapiens
-
isoform HDAC8
0.00028
suberoylanilide hydroxamic acid
Homo sapiens
37°C
0.0003
suberoylanilide hydroxamic acid
Homo sapiens
mutant H843Y
0.004
suberoylanilide hydroxamic acid
Homo sapiens
isoform HDAC8
0.113
suberoylanilide hydroxamic acid
Homo sapiens
wild type
0.0000006
trichostatin A
Plasmodium falciparum
-
0.0000006
trichostatin A
Homo sapiens
isoform HDAC3
0.0000015
trichostatin A
Homo sapiens
isoform HDAC1
0.0000028
trichostatin A
Candida albicans
-
pH 8.0, 37°C, recombinant enzyme
0.000003
trichostatin A
Homo sapiens
pH 8.0
0.000005
trichostatin A
Homo sapiens
-
-
0.000022
trichostatin A
Homo sapiens
-
HDAC activity in HeLa nuclear cell extracts, 25°C, pH 8.0
0.00004
trichostatin A
Homo sapiens
-
isoform HDAC8
0.00004
trichostatin A
Homo sapiens
mutant H843Y
0.000041
trichostatin A
Homo sapiens
-
HeLa cell nuclear extract
0.00006
trichostatin A
Homo sapiens
-
isoform HDAC1
0.0003
trichostatin A
Homo sapiens
wild type
0.00049
trichostatin A
Homo sapiens
isoform HDAC8
0.008
trichostatin A
Homo sapiens
-
recombinant HDAC3 in complex with CoR1, pH and temperature not specified in the publication
0.0008
tubacin
Homo sapiens
mutant H843Y
0.225
tubacin
Homo sapiens
wild type
0.4
Valproic acid
Homo sapiens
-
isoform HDAC1, pH 8.0, 37°C
0.995
Valproic acid
Homo sapiens
-
-
0.00003
vorinostat
Homo sapiens
-
HDAC1
0.000043
vorinostat
Homo sapiens
-
HDAC6
0.000057
vorinostat
Homo sapiens
-
HDAC3
0.000082
vorinostat
Homo sapiens
-
HDAC2
0.0017
vorinostat
Homo sapiens
-
HDAC8
0.01
vorinostat
Homo sapiens
-
HDAC7, larger than 0.010
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
evolution
-
Set3C is a conserved nuclear complex, Set3 interacts with Hos2
evolution
A0A0R0FIH2, A0A0R0H2W2, A0A0R0JU82, A0A0R0K0I2, I1JB12, I1JZJ1, I1K037, I1LFN1, I1LKU7, I1LTZ2, I1LWR2, I1MTD8, I1MUF8, I1MXC3, K7K0Q1, K7KKZ9, K7KL00, K7KR69 GmHDACs fall into three major groups previously named RPD3/HDA1, SIR2, and HD2, phylogenetic analysis. Chromosomal localization and duplications of HDAC genes in soybean, overview
evolution
histone deacetylase 8 (HDAC8) is a member of the class I acetyl-lysine deacetylase (HDAC) family
evolution
human histone deacetylases belong to all three known classes, class I: HDAC1, HDAC2, HDAC3, HDAC8, class II: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10, and class III: HDAC11
evolution
the enzyme belongs to the histone deacetylase (HDAC) superfamily
evolution
the enzyme belongs to the RPD3/HDA1-like superfamily of histone deacetylases (HDACs)
evolution
the protruded arm regions are conserved among the Hda1 homologies, and residues Ile512, Ile523 and Leu525 that play key role in the domain-domain interaction are relatively conserved. The ARB2 domain of Hda1 shows structural similarity to the alpha/beta fold hydrolases
evolution
-
the enzyme belongs to the histone deacetylase (HDAC) superfamily
-
evolution
-
the enzyme belongs to the histone deacetylase (HDAC) superfamily
-
evolution
-
the enzyme belongs to the histone deacetylase (HDAC) superfamily
-
evolution
-
the enzyme belongs to the histone deacetylase (HDAC) superfamily
-
evolution
-
the enzyme belongs to the histone deacetylase (HDAC) superfamily
-
evolution
-
the enzyme belongs to the histone deacetylase (HDAC) superfamily
-
evolution
-
the protruded arm regions are conserved among the Hda1 homologies, and residues Ile512, Ile523 and Leu525 that play key role in the domain-domain interaction are relatively conserved. The ARB2 domain of Hda1 shows structural similarity to the alpha/beta fold hydrolases
-
evolution
-
the enzyme belongs to the histone deacetylase (HDAC) superfamily
-
malfunction
-
alkylation (carbonylation) of conserved cysteine residues in HDAC1, -2 and -3 antagonizes their deacetylase activity and transcriptional co-repressor function
malfunction
down-regulation of HDAC gene HDA710 induces a semi-dwarf phenotype, down-regulation of HDAC gene HDA704 affects plant height and flag leaf development
malfunction
-
down-regulation of HDAC gene HDA710 induces a semi-dwarf phenotype, down-regulation of HDAC gene HDA704 affects plant height and flag leaf development
malfunction
-
HDAC inhibition improves DELTAF508 cystic fibrosis transmembrane conductance regulator stability and trafficking, silencing of HDAC2 and HDAC3 causes a 2.5fold and 1.5fold increase in DELTAF508 cystic fibrosis transmembrane conductance regulator mRNA, respectively, as well as an about 5fold increase in total DELTAF508 protein. Silencing of HDAC1 induces a 1.4fold stimulation of iodide efflux. In contrast, silencing of HDAC7 exhibits a 3.6fold stimulation of cAMP-mediated iodide efflux comparable to 30°C efflux
malfunction
-
HDAC1 and HDAC2 with carboxy-terminal domains deleted, retain enzymatic activity but are unable to repress cartilage gene expression
malfunction
-
HDAC7 knockdown causes increased nuclear beta-catenin, decreased transcription of HDAC7, decreased expression of E2F2, cyclin-D1 and cyclin-E2, and increased retinoblastoma protein
malfunction
-
inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer
malfunction
-
inhibition of SIRT1 activity leads to a recovery from the intrinsic repressive activity of orphan nuclear receptor small heterodimer partner (SHP) but not of DAX1. Inhibition of SIRT1 significantly diminishes the repressive effect of SHP on liver receptor homolog 1 transactivity. Inhibition of SIRT1 activity significantly reverses SHP-mediated inhibition of bile-acid synthesis by liver receptor homolog 1 overexpression
malfunction
-
knockdown of HDAC1 can generate a remarkable defect in proliferation and also can significantly induce apoptosis and S-phase arrest in PaTu-8988 cells
malfunction
-
knockdown of HDAC10 significantly increases the mRNA expression levels of thioredoxin-interacting protein and induces release of cytochrome c and activated apoptotic signaling molecules through accumulation of reactive oxygen species in SNU-620 human gastric cancer cells
malfunction
-
short hairpin-RNA silencing of either HDAC2 or HDAC4 is sufficient to induce p21 expression
malfunction
-
suppression of HDAC3 reduces the migration and induces the expression of E-cadherin in ovarian cancer cells
malfunction
-
while brain development and adult stem cell fate are normal upon conditional deletion of HDAC2 or in mice lacking the catalytic activity of HDAC2, neurons derived from both zones of adult neurogenesis die at a specific maturation stage
malfunction
-
deletion of Hos2, the catalytic subunit of the Set3 complex, produces a phenotype resembling inhibition of the Set3C by trichostatin-A
malfunction
depleting maternal isozyme HDAC2 results in hyperacetylation of H4K16, while normal deacetylation of other lysine residues of histone H3 or H4 is observed, and defective chromosome condensation and segregation during oocyte maturation occurs in a subpopulation of oocytes, leading to increased incidence of aneuploidy likely accounts for the observed sub-fertility of mice harboring Hdac2-defective oocytes. The infertility of mice harboring Hdac1-/+/Hdac2-/- oocytes is attributed to failure of those few eggs that properly mature to metaphase II to initiate DNA replication following fertilization. Hdac1-/+/Hdac2-/- eggs are fertilized but fail to initiate DNA replication. The increased amount of acetylated H4K16 likely impairs kinetochore function in oocytes lacking isozyme HDAC2 because kinetochores in mutant oocytes are less able to form coldstable microtubule attachments and less CENP-A is located at the centromere. Phenotype, overview
malfunction
hda9 and hda19 mutants show a warm-temperature-insensitive phenotype at 27°C, whereas hda15 plants displays a constitutive warm-temperature-induced phenotype at 20°C and an enhanced thermal response at 27°C. Hda9 mutation leads to differential expression of a large number of genes at 20°C and impaired induction of warm-temperature-responsive genes at 27°C. The hda15-1, hda9-1, hda9-2 and hda19 mutants display distinct hypocotyl elongation phenotypes at 20°C and 27°C under short-day conditions
malfunction
hda9 and hda19 mutants show a warm-temperature-insensitive phenotype at 27°C, whereas hda15 plants displays a constitutive warm-temperature-induced phenotype at 20°C and an enhanced thermal response at 27°C. The hda19 mutation leads to upregulation of genes mostly related to stress response at both 20°C and 27°C. The hda15-1, hda9-1, hda9-2 and hda19 mutants display distinct hypocotyl elongation phenotypes at 20°C and 27°C under short-day conditions
malfunction
histone deacetylase 7 (HDAC7) controls the thymic effector programming of natural killer T (NKT) cells, and interference with this function contributes to tissue-specific autoimmunity. Gain of HDAC7 function in thymocytes blocks both negative selection and NKT development, and diverts Va14/Ja18 TCR transgenic thymocytes into a Tconv-like lineage. Conversely, HDAC7 deletion promotes thymocyte apoptosis and causes expansion of innate-effector cells, mechanisms, overview. A mutation in HDAC7 can create problems only for specific organs in the body. In humans, mutations in HDAC7 are also associated with autoimmune disorders of the digestive tract and liver. These include inflammatory bowel diseases such as ulcerative colitis or Crohn's disease. Alteration of HDAC7 function dysregulates thymic innate effector programming and interferes with iNKT development
malfunction
histone deacetylase 7 (HDAC7) controls the thymic effector programming of natural killer T (NKT) cells, and interference with this function contributes to tissue-specific autoimmunity. Gain of HDAC7 function in thymocytes blocks both negative selection and NKT development, and diverts Va14/Ja18 TCR transgenic thymocytes into a Tconv-like lineage. Conversely, HDAC7 deletion promotes thymocyte apoptosis and causes expansion of innate-effector cells, mechanisms, overview. Alteration of HDAC7 function dysregulates thymic innate effector programming and interferes with iNKT development. While the wild-type-derived population reconstitutes hepatic iNKT cells efficiently, HDAC7-DELTAP bone marrow makes almost no contribution to this compartment in the liver, where iNKT cells are most abundant. This is also true in the thymus and spleen, demonstrating that the abnormalities observed in the intact transgenic mice are due to a cell-autonomous mechanism. Analysis of effects of loss of HDAC7 in the thymus on these phenotypes. Deletion of Hdac7 does not result in expansion of NK1.1-expressing T-cells, but significant abnormalities in the effector programming of non-tetramer-reactive thymocytes are observed
malfunction
K701 rpd3DELTA and K701 hda1DELTA alter the response to oxygen of isoamyl acetate production
malfunction
knockdown of HDT1/2 (hdt1,2i) results in an earlier switch and causes a reduced root meristem cell number. Overexpression of GA2ox2 in the RM phenocopies the hdt1,2i phenotype. Conversely, knockout of GA2ox2 partially rescues the root growth defect of hdt1,2i. The hdt1,2i-1 root tip has a gibberellin-deficient phenotype
malfunction
perturbation of the dimer interface abolishes the histone binding ability of the ARB2 domain
malfunction
RNAi-mediated HDAC1 knockdown in Gnatocerus cornutus larvae causes specific curtailment of mandibles in adults, whereas HDAC3 knockdown leads to hypertrophy. These knockdowns confer opposite effects on wing size, but little effect on the size of the core body and genital modules. PcG RNAi also reduces adult mandible size. Phenotypes, overview
malfunction
the hda15 mutation results in upregulation of many warm temperature-responsive as well as metabolic genes at 20°C and 27°C. HDA15 is associated with thermosensory mark genes at 20°C. That the association is decreased after shifting to 27°. In addition, the hda15 mutation also leads to upregulation of many metabolic genes and accumulation of primary metabolites. The hda15-1, hda9-1, hda9-2 and hda19 mutants display distinct hypocotyl elongation phenotypes at 20°C and 27°C under short-day conditions. Additive effects of the hda15-1/hfr1 double mutations on the hypocotyl and petiole lengths
malfunction
transcript levels of ILV2, ILV3 and ILV5 are elevated in Rpd3L-deficient strains (rpd3DELTA, ume1DELTA, dep1DELTA, and sds3DELTA) but not in Rpd3S-single deficient strain (rco1DELTA and eaf3DELTA) compared to wild-type K701. The transcript levels of ATF2, a minor alcohol acetyltransferase, are higher in the rpd3DELTA and ume1DELTA strains than in the parental strain. K701 rpd3DELTA and K701 hda1DELTA alter the response to oxygen of isoamyl acetate production
malfunction
-
histone deacetylase 7 (HDAC7) controls the thymic effector programming of natural killer T (NKT) cells, and interference with this function contributes to tissue-specific autoimmunity. Gain of HDAC7 function in thymocytes blocks both negative selection and NKT development, and diverts Va14/Ja18 TCR transgenic thymocytes into a Tconv-like lineage. Conversely, HDAC7 deletion promotes thymocyte apoptosis and causes expansion of innate-effector cells, mechanisms, overview. Alteration of HDAC7 function dysregulates thymic innate effector programming and interferes with iNKT development. While the wild-type-derived population reconstitutes hepatic iNKT cells efficiently, HDAC7-DELTAP bone marrow makes almost no contribution to this compartment in the liver, where iNKT cells are most abundant. This is also true in the thymus and spleen, demonstrating that the abnormalities observed in the intact transgenic mice are due to a cell-autonomous mechanism. Analysis of effects of loss of HDAC7 in the thymus on these phenotypes. Deletion of Hdac7 does not result in expansion of NK1.1-expressing T-cells, but significant abnormalities in the effector programming of non-tetramer-reactive thymocytes are observed
-
malfunction
-
transcript levels of ILV2, ILV3 and ILV5 are elevated in Rpd3L-deficient strains (rpd3DELTA, ume1DELTA, dep1DELTA, and sds3DELTA) but not in Rpd3S-single deficient strain (rco1DELTA and eaf3DELTA) compared to wild-type K701. The transcript levels of ATF2, a minor alcohol acetyltransferase, are higher in the rpd3DELTA and ume1DELTA strains than in the parental strain. K701 rpd3DELTA and K701 hda1DELTA alter the response to oxygen of isoamyl acetate production
-
malfunction
-
perturbation of the dimer interface abolishes the histone binding ability of the ARB2 domain
-
malfunction
-
K701 rpd3DELTA and K701 hda1DELTA alter the response to oxygen of isoamyl acetate production
-
malfunction
-
deletion of Hos2, the catalytic subunit of the Set3 complex, produces a phenotype resembling inhibition of the Set3C by trichostatin-A
-
metabolism
nitrative/oxidative stress reduce HDAC2 expression via nitration of distinct tyrosine residues. Peroxynitrite, hydrogen peroxide and cigarette smoke-conditioned medium reduce HDAC2 expression in A549 epithelial cells in vitro. This reduction is due to increased proteasomal degradation following ubiquitination rather than reduction of mRNA expression or stability
metabolism
epigenetic modifications including DNA methylation and histone post-translational modifications are closely associated with bladder cancer (BC) initiation and development, some HDACs play roles in the tumorigenicity of bladder cancer, overview. HDAC4 and HDAC9 expression is inversely correlated with Forkhead Box A1 (FOXA1), an important transcription factor in maintaining urothelial differentiation, and peroxisome proliferator-activated receptor gamma (PPARG), a steroid hormone receptor known for its oncogenic role in the development of BC
metabolism
epigenetic modifications including DNA methylation and histone post-translational modifications are closely associated with bladder cancer initiation and development, some HDACs play roles in the tumorigenicity of bladder cancer, overview
metabolism
metabolite profiling, mass spectrometric analysis
metabolism
two Arabidopsis thaliana paralogues encoding plant-specific histone deacetylases, HDT1 and HDT2, regulate a second switch from transit-amplifying cells to expanding cells
physiological function
-
regulator of cellular pathways like response to stress, protein folding, microtubule stability and cell migration
physiological function
-
ectopic overexpression of HDAC6 isotype increases the levels of phosphorylated epidermal growth factor receptor and phosphorylated AKT expression. HDAC6 plays an important role in the modulation of radiation response of epidermal growth factor receptor and human epidermal growth factor receptor 2-activated cells
physiological function
-
HDAC catalyze the removal of acetyl groups from core histones inducing local condensation of chromatin. Therefore, HDACs are generally considered repressors of transcription. Coiled-coil domain-containing protein 6 physically interacts with HDAC1 on the amphiregulin promoter. Coiled-coil domain-containing protein 6 requires HDAC1 activity to repress cAMP responsive element binding protein 1 target gene transcription
physiological function
-
HDAC1 and HDAC2 repress aggrecan and collagen 2(alpha1) expression but differ in their repression of collagen 9(alpha1), collagen 11(alpha1), dermatopontin, and cartilage oligomeric matrix protein. Carboxy-terminal domains of HDAC1 and HDAC2 are not required for enzymatic activity in vitro but are required for optimal deacetylation in vivo and repression of cartilage-specific gene expression
physiological function
-
HDAC1 enhances cell proliferation of ovarian cancer cells, the expression of HDAC1 and HDAC2 is correlated with the proliferation marker Ki-67 expression, and HDAC3 stimulates cell migration with downregulation of E-cadherin in ovarian carcinoma
physiological function
-
HDAC10 is involved in transcriptional downregulation of thioredoxin-interacting protein, leading to altered reactive oxygen species signaling in human gastric cancer cells
physiological function
-
HDAC2 and HDAC1 are required for glucocorticoid receptor-mediated gene activation. HDAC2, however, is regulated through a different mechanism from that of HDAC1. Acetylated HDAC1 can trans-regulate HDAC2 through heterodimerization. Both HDAC1 and HDAC2 are required for mouse mammary tumor virus transcription
physiological function
-
HDAC6 is necessary for protein aggregate formation and degradation
physiological function
-
HDAC6 mediates TGF-beta1-induced epithelial-mesenchymal transition in A-549 cells. Splicing variant HDAC6p114 is required for TGF-beta1-activated gene expression associated with epithelial-mesenchymal transition in A-549 cells
physiological function
-
HDAC7 overexpression has the ability to trump vascular endothelial growth factor signaling to inhibit endothelial cell proliferation, overexpression of HDAC7 leads to decreased nuclear beta-catenin and decreased activity of beta-catenin-dependent effectors and an associated inhibition of endothelial cell proliferation
physiological function
-
HDAC7 plays a central role in restoration of DELTAF508 cystic fibrosis transmembrane conductance regulator function
physiological function
-
HDACs regulate hepatocyte growth factor-induced urokinase plasminogen activator and matrix metalloproteinase-9 expression through a protein kinase C-dependent signal pathway in gastric cancer cells
physiological function
-
orphan nuclear receptor small heterodimer partner (SHP) interacts and co-localizes specifically with SIRT1 in vivo. SHP recruits SIRT1 on liver receptor homolog 1 target gene promoters and SIRT1 deacetylates template-dependent histone H3 and H4 to inhibit transcription of liver receptor homolog 1 target genes
physiological function
-
SIRT6 is a site-specific histone deacetylase that regulates chromatin structure. SIRT6 is implicated in fundamental biological processes in aging, including maintaining telomere integrity, fine-tuning aging-associated gene expression programs, preventing genomic instability, and maintaining metabolic homeostasis. The N-terminal extension of SIRT6 is critical for chromatin association and intrinsic catalytic activity
physiological function
-
the catalytic function of HDAC2 is required in adult but not embryonic neurogenesis. HDAC2 is critically required to silence progenitor transcripts during neuronal differentiation of adult generated neurons
physiological function
the HDAC gene HDA703 is involved in histone H4 acetylation in rice, HDAC gene HDA703 has a function during plant reproductive development and seed morphology, HDA702/HDAC1 and HDA710 play a similar but important role in root and vegetative growth
physiological function
-
the HDAC gene HDA703 is involved in histone H4 acetylation in rice, HDAC gene HDA703 has a function during plant reproductive development and seed morphology, HDA702/HDAC1 and HDA710 play a similar but important role in root and vegetative growth
physiological function
-
the HDAC1 overexpression plays an important role in tumorigenesis of pancreatic cancer
physiological function
-
activity of histone deacetylases influences splice site selection. Splicing of 700 genes in heLa cells is altered after HDAC inhibition. HDAC inhibition induces histone H4 acetylation and increases RNA Polymerase II processivity along an alternatively spliced element. In addition, HDAC inhibition reduces co-transcriptional association of the splicing regulator SRp40 with the target fibronectin exon. The depletion of HDAC1 has similar effect on fibronectin alternative splicing as global HDAC inhibition. This effect is reversed upon expression of mouse HDAC1 but not a catalytically inactive mutant
physiological function
-
embryos injected with mRNA encoding a dominant-negative form of histone deacetylase lacked expression of gene Nodal related, Nr1, and exhibit randomized sidedness of the heart and viscera at stage 45. Pharmacological blockade of HDACs implicates cleavage stages as the active period. Inhibition during these early stages is correlated with an absence of Nr1 expression at stage 21, high levels of heterotaxia at stage 45, and the deposition of the epigenetic marker H3K4me2 on the Nr1 gene. The known HDAC partner protein Mad3 is a 5HT-binding regulator. While Mad3 overexpression leads to an absence of Nr1 transcription and randomizes the left-right axis, a mutant form of Mad3 lacking 5HT binding sites is not able to induce heterotaxia
physiological function
-
HDAC9 gene knockdown produces dose-dependent gamma-globin gene silencing over an 80-320 nM range. Enforced expression of HDAC9 produces a dose-dependent 2.5fold increase in gammaglobin mRNA. HDAC9 binds in vivo in the upstream Ggamma-globin gene promoter region. Treatment of primary erythroid progenitors with HDAC9 siRNA results in 40 and 60% gamma-globin gene silencing in day 11 (early) and day 28 (late) progenitors, respectively. Enforced HDAC9 expression increases gamma-globin mRNA levels by 2.5fold with a simultaneous 7fold increase in fetal hemoglobin
physiological function
-
in liver, class IIa HDACs HDAC4, 5, and 7, are phosphorylated and excluded from the nucleus by AMPK family kinases. In response to the fasting hormone glucagon, these HDACs are rapidly dephosphorylated and translocated to the nucleus where they associate with the promoters of gluconeogenic enzymes such as G6Pase. In turn, HDAC4/5 recruit HDAC3, which results in the acute transcriptional induction of these genes via deacetylation and activation of FOXO family transcription factors. Loss of class IIa HDACs in murine liver results in inhibition of FOXO target genes and lowers blood glucose, resulting in increased glycogen storage
physiological function
-
Lysine-specific demethylase 1 has a repressive role in proinflammatory cytokine expression such as IL1alpha, IL1b,eta IL6 and IL8 and classical complement components. HDAC1 and lysine-specific demethylase 1 synergistically regulate these inflammatory-related genes
physiological function
mutation of HDA-1 by repeat-induced point mutation causes partial loss of DNA methylation. The site-specific loss of DNA methylation in hda-1 correlates with loss of H3 lysine 9 trimethylation and increased H3 acetylation. In addition, an increase in H2B acetylation is observed by two-dimensional gel electrophoresis of histones of the hda-1 mutant
physiological function
-
role for Clr6 in transcriptional regulation of amino acid permease gene per1. When ammonia is used as the nitrogen source, low levels of per1 are transcribed and histones in the coding and surrounding regions of per1 are acetylated. In the presence of proline, histones at per1 are deacetylated in a Clr6-dependent manner
physiological function
-
simultaneous treatment with IFNalpha2 and inhibitor trichostatin A, as well as combined HDAC1/HDAC2 silencing, restores STAT3-dependent reporter gene and endogenous gene expression, strongly suggesting that HDAC1 and HDAC2 are directly involved in repressing IFNalpha2-activated STAT3. In contrast, HDAC1 and HDAC2 activities are required for ISGF3-dependent gene expression. HDAC1 and HDAC2 differentially modulate STAT activity in response to IFNalpha2, while they are required for the induction of ISGF3-responsive genes, they impair the transcription of STAT3-dependent genes
physiological function
-
Sir2 is involved in protection against Hog1-induced cell death and can suppress Hog1-induced reactive oxygen species accumulation. Therefore, cell death seems to be dictated by the balance of reactive oxygen species induced by Hog1 and the protective effect of Sir2. Prolonged activation of stress-activated protein kinase leads to cell death, by causing accumulation of reactive oxygen species. Mutations of the SCF-CDC4 ubiquitin ligase complex suppress cell death by preventing the degradation of Msn2 and Msn4 transcription factors. Accumulation of transcription factors Msn2 and Msn4 leads to the induction of PNC1, which is an activator of the Sir2 histone acetylase
physiological function
-
Sirt1 inhibits T cell activation by suppressing the transcription of Bcl2-associated factor 1, Bclaf1, a protein required for T cell activation. Sirt1-null T cells have increased acetylation of the histone 3 lysine 56 residue, H3K56, at the bclaf1 promoter, as well as increasing Bclaf1 transcription. Sirt1 binds to bclaf1 promoter upon T cell receptor/CD28 stimulation by forming a complex with histone acetyltransferase p300 and NF-kappaB transcription factor Rel-A. The recruitment of Sirt1, but not p300, requires Rel-A. Knockdown of Bclaf1 suppresses the hyperactivation observed in Sirt1-/- T cells. Therefore, Sirt1 negatively regulates T cell activation via H3K56 deacetylation at the promoter region to inhibit transcription of Bclaf1
physiological function
the hda-2 mutation does not affect DNA methylation at any region tested, and the deletion and repeat-induced point mutation alleles give identical results
physiological function
the hda-3 mutation leads to global increases in histones H3 and H4 acetylation levels and to partial loss of DNA methylation
physiological function
the hda-4 mutation leads to global increases in histones H3 and H4 acetylation levels
physiological function
histone deacetylase 2 regulates chromosome segregation and kinetochore function via H4K16 deacetylation during oocyte maturation in mouse. HDAC2 is the major isozyme that regulates global histone acetylation during oocyte development and is largely responsible for the deacetylation of H4K16 during maturation. Histone deacetylation that occurs during oocyte maturation is critical for proper chromosome segregation
physiological function
-
the enzyme activity promotes liver regeneration by regulating hepatocellular cell cycle progression at a step downstream of cyclin D1 induction
physiological function
-
the Hos2/Set3 histone deacetylase complex (Set3C) plays a key role in the conversion of white phase to virulent opaque phase in Candida albicans. Azole resistance can be reversed by the co-administration of a histone deacetylase inhibitor, suggesting that resistance is mediated by epigenetic mechanisms possibly involving the fungal deacetylase Hos2
physiological function
-
the Set3 complex acts as a repressor of hyphal differentiation and its function requires functional cAMP/PKA signaling, Set3C also controls morphogenesis through a transcription factor cluster, it is a co-factor of glycolysis and morphogenesis regulators, Set3C recruitment predicts induction and depletion predicts repression of yeast-to-hypha transition, molecular mechanism, overview. The Set3C decorates highly transcribed genes. The four phase-specific Set3C target transcription factors form a core transcriptional circuit
physiological function
Arabidopsis thaliana histone deacetylase genes HDA9, HDA15 and HDA19 play distinct roles in plant response to elevated ambient temperature. The histone deacetylases target to different sets of genes and play distinct roles in plant response to elevated ambient temperature, overview
physiological function
Arabidopsis thaliana histone deacetylase genes HDA9, HDA15 and HDA19 play distinct roles in plant response to elevated ambient temperature. The histone deacetylases target to different sets of genes and play distinct roles in plant response to elevated ambient temperature, overview. HDA15 is associated with thermosensory mark genes at 20°C. HDA15 is a direct repressor of plant thermal-responsive genes at normal temperature. HDA15 interacts with the transcription factor HFR1 (long Hypocotyl in Far Red1) to cooperatively repress warm-temperature response. HDA15 may be recruited by HFR1 to chromatin to epigenetically repress downstream target genes involved in hypocotyl elongation during plant response to low light and high temperature. HDA15 may stabilize HFR1 or enhances its function in negatively regulating PIF proteins that promote hypocotyl elongation during plant response to the growth conditions
physiological function
Arabidopsis thaliana histone deacetylase genes HDA9, HDA15 and HDA19 play distinct roles in plant response to elevated ambient temperature. The histone deacetylases target to different sets of genes and play distinct roles in plant response to elevated ambient temperature, overview. The hda9 mutation also leads to upregulation of many metabolic genes and accumulation of primary metabolites
physiological function
Hda1 is the catalytic core component of the H2B- and H3-specific histone deacetylase (HDAC) complex from Saccharomyces cerevisiae, which is involved in the epigenetic repression and plays a crucial role in transcriptional regulation and developmental events
physiological function
HDA1 might be involved in the epigenetic regulation of stress resistance genes that comprise the responses to osmotic stress and abscisic acid
physiological function
HDAC genes are non-essential in yeast, functional analysis of genes, RPD3, HDA1, SIR2, and HST1 in the Sake yeast strain Kyokai No. 701 (K701). RPD3 and Hda1 are translation regulatory proteins and histone deacetylases. Rpd3 and Hda1 may regulate isoamyl acetate production via oxygen in a Rox1-independent manner. Yeast HDACs, and maybe also HAT and their regulatory subunits, are keys to determine fermentation characteristics, and these genes may be an important target for improvement of yeast strains used for alcoholic beverage production
physiological function
HDAC genes are non-essential in yeast, functional analysis of genes, RPD3, HDA1, SIR2, and HST1 in the Sake yeast strain Kyokai No. 701 (K701). RPD3 and Hda1 are translation regulatory proteins and histone deacetylases. Rpd3L-dependent regulation of genes ILV2, ILV3 and ILV5. Rpd3 and Hda1 may regulate isoamyl acetate production via oxygen in a Rox1-independent manner. Yeast HDACs, and maybe also HAT and their regulatory subunits, are keys to determine fermentation characteristics, and these genes may be an important target for improvement of yeast strains used for alcoholic beverage production
physiological function
histone deacetylase 7 mediates tissue-specific autoimmunity via control of innate effector function in invariant natural killer T cells. HDAC7 binds transcription factor promyelocytic leukemia zinc finger protein (PLZF, ZBTB16) and modulates PLZF-dependent transcription. Autoimmune diseases are observed in HDAC7 gain-of-function in mice. Association between HDAC7 and hepatobiliary autoimmunity. Tconv development is regulated by the class IIA histone deacetylase histone deacetylase 7 (HDAC7), a TCR signal-regulated corepressor abundantly expressed in thymocytes. The activity of HDAC7 is controlled by nuclear exclusion in response to phosphorylation of conserved serine residues in their N-terminal adapter domains. HDAC7 regulates the effector programming of NKT cells in a manner that mirrors the function of PLZF. HDAC7 and PLZF inversely regulate a shared innate effector gene network that is highly relevant to autoimmune disease. HDAC7 nuclear export licenses innate effector development. HDAC7 serves as a gatekeeper of this developmental fate decision in the thymus
physiological function
histone deacetylase 7 mediates tissue-specific autoimmunity via control of innate effector function in invariant natural killer T cells. HDAC7 binds transcription factor promyelocytic leukemia zinc finger protein (PLZF, ZBTB16) and modulates PLZF-dependent transcription. HDAC7 and many of its transcriptional targets are human risk loci for IBD and PSC, autoimmune diseases that strikingly resemble the disease observed in HDAC7 gain-of-function in mice. Association between HDAC7 and hepatobiliary autoimmunity. Tconv development is regulated by the class IIA histone deacetylase histone deacetylase 7 (HDAC7), a TCR signal-regulated corepressor abundantly expressed in thymocytes. The activity of HDAC7 is controlled by nuclear exclusion in response to phosphorylation of conserved serine residues in their N-terminal adapter domains. HDAC7 regulates the effector programming of NKT cells in a manner that mirrors the function of PLZF. HDAC7 and PLZF inversely regulate a shared innate effector gene network that is highly relevant to autoimmune disease. HDAC7 nuclear export licenses innate effector development. HDAC7 serves as a gatekeeper of this developmental fate decision in the thymus
physiological function
histone deacetylases (HDACs) and polycomb group (PcG) proteins preferentially influence the size of mandibles (exaggerated male weapon) and demonstrate nutrition-dependent hypervariability in the broad-horned flour beetle, Gnatocerus cornutus. The plastic development of exaggerated traits is controlled in a module-specific manner by HDACs. The two HDACs, HDAC1 and HDAC3, appear to regulate size plasticity of mandibles and wings antagonistically, irrespective of which stage is perturbed, overview
physiological function
histone deacetylases (HDACs) and polycomb group (PcG) proteins preferentially influence the size of mandibles (exaggerated male weapon) and demonstrate nutrition-dependent hypervariability in the broad-horned flour beetle, Gnatocerus cornutus. The two HDACs, HDAC1 and HDAC3, appear to regulate size plasticity of mandibles and wings antagonistically, irrespective of which stage is perturbed, overview
physiological function
histone deacetylases (HDACs) are specifically responsible for the deacetylation of lysine residues at the N-terminal regions of the core histones (H2A, H2B, H3 and H4). In addition, HDACs may deacetylate other non-histone proteins and thus are involved in several cellular processes (e.g. differentiation, apoptosis, cancer development)
physiological function
A0A0R0FIH2, A0A0R0H2W2, A0A0R0JU82, A0A0R0K0I2, I1JB12, I1JZJ1, I1K037, I1LFN1, I1LKU7, I1LTZ2, I1LWR2, I1MTD8, I1MUF8, I1MXC3, K7K0Q1, K7KKZ9, K7KL00, K7KR69 histone deacetylases play roles in response to abiotic stresses in soybean. Histone deacetylases (HDACs) function as key epigenetic factors in repressing the expression of genes in multiple aspects of plant growth, development and plant response to abiotic or biotic stresses. Differential changes in GmHDACs transcripts accumulation occur in response to several abiotic cues, indicating that these epigenetic modifiers might potentially be part of a dynamic transcriptional response to stress in soybean. The levels of histone marks associated with plant HDACs are modulated by cold and heat in this legume
physiological function
increased expression of HDAC4 and -9 in patients with invasive squamous cell carcinoma supporting the idea that class IIa HDACs are important in the development of a basal molecular subtype and squamous differentiation in bladder cancer
physiological function
increased expression of HDAC4 and HDAC9 in patients with invasive squamous cell carcinoma supporting the idea that class IIa HDACs are important in the development of a basal molecular subtype and squamous differentiation in bladder cancer
physiological function
plant-specific histone deacetylases HDT1/2 regulate gibberellin2-oxidase2 gene expression to control Arabidopsis thaliana meristem cell number. HDT1/2 directly negatively regulate the acetylation level of the C19-gibberellin2-oxidase2 (GA2ox2) locus and repress the expression of GA2ox2 in the RM and elongation zone, transcriptome analyses. HDT1 and 2 function as part of a mechanism that modulates root growth in response to environmental factors
physiological function
the active site metal identity alters histone deacetylase 8 substrate selectivity, which may be a potential regulatory mechanism
physiological function
-
histone deacetylase 7 mediates tissue-specific autoimmunity via control of innate effector function in invariant natural killer T cells. HDAC7 binds transcription factor promyelocytic leukemia zinc finger protein (PLZF, ZBTB16) and modulates PLZF-dependent transcription. Autoimmune diseases are observed in HDAC7 gain-of-function in mice. Association between HDAC7 and hepatobiliary autoimmunity. Tconv development is regulated by the class IIA histone deacetylase histone deacetylase 7 (HDAC7), a TCR signal-regulated corepressor abundantly expressed in thymocytes. The activity of HDAC7 is controlled by nuclear exclusion in response to phosphorylation of conserved serine residues in their N-terminal adapter domains. HDAC7 regulates the effector programming of NKT cells in a manner that mirrors the function of PLZF. HDAC7 and PLZF inversely regulate a shared innate effector gene network that is highly relevant to autoimmune disease. HDAC7 nuclear export licenses innate effector development. HDAC7 serves as a gatekeeper of this developmental fate decision in the thymus
-
physiological function
-
HDAC genes are non-essential in yeast, functional analysis of genes, RPD3, HDA1, SIR2, and HST1 in the Sake yeast strain Kyokai No. 701 (K701). RPD3 and Hda1 are translation regulatory proteins and histone deacetylases. Rpd3L-dependent regulation of genes ILV2, ILV3 and ILV5. Rpd3 and Hda1 may regulate isoamyl acetate production via oxygen in a Rox1-independent manner. Yeast HDACs, and maybe also HAT and their regulatory subunits, are keys to determine fermentation characteristics, and these genes may be an important target for improvement of yeast strains used for alcoholic beverage production
-
physiological function
-
Hda1 is the catalytic core component of the H2B- and H3-specific histone deacetylase (HDAC) complex from Saccharomyces cerevisiae, which is involved in the epigenetic repression and plays a crucial role in transcriptional regulation and developmental events
-
physiological function
-
HDAC genes are non-essential in yeast, functional analysis of genes, RPD3, HDA1, SIR2, and HST1 in the Sake yeast strain Kyokai No. 701 (K701). RPD3 and Hda1 are translation regulatory proteins and histone deacetylases. Rpd3 and Hda1 may regulate isoamyl acetate production via oxygen in a Rox1-independent manner. Yeast HDACs, and maybe also HAT and their regulatory subunits, are keys to determine fermentation characteristics, and these genes may be an important target for improvement of yeast strains used for alcoholic beverage production
-
physiological function
-
the Hos2/Set3 histone deacetylase complex (Set3C) plays a key role in the conversion of white phase to virulent opaque phase in Candida albicans. Azole resistance can be reversed by the co-administration of a histone deacetylase inhibitor, suggesting that resistance is mediated by epigenetic mechanisms possibly involving the fungal deacetylase Hos2
-
additional information
-
enzyme Hos2 is not inhibited by class I inhibitors such as MS-275
additional information
-
isoform-specific regulation of zinc-dependent histone deacetylase expression, subcellular localization, and activity in regenerating liver. The signals that regulate the PH-induced metabolic response to hepatic insufficiency are not downstream, but might be upstream, of the target of suberoylanilide hydroxyamic acid's anti-regenerative activity
additional information
enzyme structure homology modelling
additional information
enzyme structure homology modelling
additional information
-
enzyme structure homology modelling
additional information
similar histones substrate conversion is observed in the presence of octameric and monomeric enzyme
additional information
-
similar histones substrate conversion is observed in the presence of octameric and monomeric enzyme
additional information
the ARB2 domain displays an alpha/beta sandwich architecture with an arm protruding outside. Two ARB2 domain molecules form a compact homodimer via the arm elements, and assemble as an inverse V shape. The pull-down and ITC results reveal that the ARB2 domain possesses the histone binding ability, recognizing both the H2A-H2B dimer and H3-H4 tetramer. the unique dimer architecture of the ARB2 domain coincides with the function for anchoring to histone. Hda1 consists of an N-terminal catalytic domain and a C-terminal non-catalytic domain (ARB2). The catalytic domain of Hda1 shows high sequence homology to the HDACs structures. Role of the C-terminal non-catalytic domain of Hda1 functioning in the deacetylation process, overview
additional information
-
the ARB2 domain displays an alpha/beta sandwich architecture with an arm protruding outside. Two ARB2 domain molecules form a compact homodimer via the arm elements, and assemble as an inverse V shape. The pull-down and ITC results reveal that the ARB2 domain possesses the histone binding ability, recognizing both the H2A-H2B dimer and H3-H4 tetramer. the unique dimer architecture of the ARB2 domain coincides with the function for anchoring to histone. Hda1 consists of an N-terminal catalytic domain and a C-terminal non-catalytic domain (ARB2). The catalytic domain of Hda1 shows high sequence homology to the HDACs structures. Role of the C-terminal non-catalytic domain of Hda1 functioning in the deacetylation process, overview
additional information
transcript analysis of genes responsible for the production of flavor components
additional information
transcript analysis of genes responsible for the production of flavor components
additional information
-
transcript analysis of genes responsible for the production of flavor components
additional information
-
transcript analysis of genes responsible for the production of flavor components
-
additional information
-
the ARB2 domain displays an alpha/beta sandwich architecture with an arm protruding outside. Two ARB2 domain molecules form a compact homodimer via the arm elements, and assemble as an inverse V shape. The pull-down and ITC results reveal that the ARB2 domain possesses the histone binding ability, recognizing both the H2A-H2B dimer and H3-H4 tetramer. the unique dimer architecture of the ARB2 domain coincides with the function for anchoring to histone. Hda1 consists of an N-terminal catalytic domain and a C-terminal non-catalytic domain (ARB2). The catalytic domain of Hda1 shows high sequence homology to the HDACs structures. Role of the C-terminal non-catalytic domain of Hda1 functioning in the deacetylation process, overview
-
additional information
-
enzyme Hos2 is not inhibited by class I inhibitors such as MS-275
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.